{
  "symbol": "BIIB",
  "frequency": "quarterly",
  "timestamp": "2025-09-19T15:39:57.385444",
  "data": {
    "cik": "875045",
    "data": [
      {
        "accessNumber": "0000875045-25-000033",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2025,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2025-01-01 00:00:00",
        "endDate": "2025-06-30 00:00:00",
        "filedDate": "2025-07-31 00:00:00",
        "acceptedDate": "2025-07-31 06:05:42",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2758800000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net of allowance for doubtful accounts of $2.9 and $2.2, respectively",
              "value": 2084000000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 2274300000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 850600000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7967700000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3098800000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 334500000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 9467500000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 6493100000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 330900000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 637700000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 28330200000
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 114800000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 408400000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2660500000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3183700000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 6283700000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 118300000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 310900000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 799600000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10696200000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 714000000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -238100000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 20135100000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 17634000000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 28330200000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 5076500000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1234300000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 833100000
            },
            {
              "concept": "biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Acquired in-process research and development, upfront and milestone expense",
              "value": 247300000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1156300000.0
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 242700000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit sharing/(loss reimbursement)",
              "value": 133100000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 34600000
            },
            {
              "concept": "us-gaap_GainLossOnDispositionOfIntangibleAssets",
              "unit": "usd",
              "label": "Gain on sale of priority review voucher, net",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherOperatingIncomeExpenseNet",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": -117100000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 4021300000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
              "unit": "usd",
              "label": "Income before income tax (benefit) expense",
              "value": 1055200000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 179900000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 875300000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc. (in USD per share)",
              "value": 5
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in USD per share)",
              "value": 5
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc. (in USD per share)",
              "value": 146300000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in USD per share)",
              "value": 146700000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -163600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -1000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustments, net of tax",
              "value": 60700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -101900000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 773400000
            },
            {
              "concept": "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
              "unit": "usd",
              "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
              "value": 22800000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 875300000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 377500000
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 3500000.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 14300000
            },
            {
              "concept": "biib_AmortizationOfInventoryStepUp",
              "unit": "usd",
              "label": "Amortization of acquired inventory step-up",
              "value": 103900000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 155900000
            },
            {
              "concept": "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
              "unit": "usd",
              "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
              "value": 22800000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -59100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -33200000
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of priority review voucher, net",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -16000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 166300000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 27900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -318700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -534700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 75500000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 420200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 63700000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sale of equity interest in Samsung Bioepis",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from sale of priority review voucher",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 10000000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 30600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": -104300000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 18200000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 1733400000
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayments of borrowings",
              "value": 1750000000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 100000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -34700000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 281200000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 102600000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-25-000018",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2025,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2025-01-01 00:00:00",
        "endDate": "2025-03-31 00:00:00",
        "filedDate": "2025-05-01 00:00:00",
        "acceptedDate": "2025-05-01 16:48:23",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2598300000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net of allowance for doubtful accounts of $1.4 and $2.2, respectively",
              "value": 1996500000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 2273900000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 757300000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7626000000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3132400000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 346400000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 9584600000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 6477100000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 307500000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 559100000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 28033100000
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 1749100000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 626100000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 391500000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2530700000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 5297400000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 4548700000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 133200000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 323400000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 751700000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 11054400000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 629900000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -174500000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 19500300000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 16978700000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 28033100000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 2431000000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 629300000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 434100000
            },
            {
              "concept": "biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Acquired in-process research and development, upfront and milestone expense",
              "value": 200700000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 572500000.0
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 111800000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit sharing/(loss reimbursement)",
              "value": 58100000
            },
            {
              "concept": "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 9600000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 35300000
            },
            {
              "concept": "us-gaap_OtherOperatingIncomeExpenseNet",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": -68400000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 2119800000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
              "unit": "usd",
              "label": "Income before income tax (benefit) expense",
              "value": 311200000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 70700000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 240500000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc. (in USD per share)",
              "value": 1
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in USD per share)",
              "value": 1
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc. (in USD per share)",
              "value": 146100000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc. (in USD per share)",
              "value": 146600000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -57800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -400000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustments, net of tax",
              "value": 19100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -38300000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 202200000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 9600000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 240500000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 183200000
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 7300000
            },
            {
              "concept": "biib_AmortizationOfInventoryStepUp",
              "unit": "usd",
              "label": "Amortization of acquired inventory step-up",
              "value": 51400000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 81000000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -27800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -40900000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -6700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 110600000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": -62000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -300500000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 69100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 53500000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 259300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 37100000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 10000000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 200000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": -47300000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 24300000
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 1300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -23000000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 189000000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 34300000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-24-000032",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2024,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2024-01-01 00:00:00",
        "endDate": "2024-09-30 00:00:00",
        "filedDate": "2024-10-30 00:00:00",
        "acceptedDate": "2024-10-30 16:31:22",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1699200000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net of allowance for doubtful accounts of $2.0 and $2.4, respectively",
              "value": 1988100000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 2469200000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 674000000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 6830500000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3210900000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 380400000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 9805500000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 6485800000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 968700000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 631400000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 28313200000
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion notes payable and term loan",
              "value": 1748100000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 499100000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 422700000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2755100000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 5425000000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and term loan",
              "value": 4545800000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 882400000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 357000000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 744100000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 11954300000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 488500000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -145700000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 18993100000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 16358900000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 28313200000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 7221200000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1726900000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1509500000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1723700000
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 295500000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit sharing/(loss reimbursement)",
              "value": 197300000
            },
            {
              "concept": "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 23800000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 24900000
            },
            {
              "concept": "us-gaap_GainLossOnDispositionOfIntangibleAssets",
              "unit": "usd",
              "label": "Gain on sale of priority review voucher, net",
              "value": 88600000.0
            },
            {
              "concept": "us-gaap_OtherOperatingIncomeExpenseNet",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": -193700000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 5606700000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
              "unit": "usd",
              "label": "Income (loss) before income tax (benefit) expense",
              "value": 1614500000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 249000000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income (loss)",
              "value": 1365500000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": 0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income (loss) attributable to Biogen Inc.",
              "value": 1365500000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings (loss) per share attributable to Biogen Inc.",
              "value": 9
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings (loss) per share attributable to Biogen Inc.",
              "value": 9
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings (loss) per share attributable to Biogen Inc.",
              "value": 145500000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings (loss) per share attributable to Biogen Inc.",
              "value": 146000000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -6200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 14000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 8000000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 1373500000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 1373500000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 23800000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income (loss)",
              "value": 1365500000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 489200000
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 20200000.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 68700000
            },
            {
              "concept": "biib_AmortizationOfInventoryStepUp",
              "unit": "usd",
              "label": "Amortization of acquired inventory step-up",
              "value": 185100000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 216100000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -99700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -22700000
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of priority review voucher, net",
              "value": 88600000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -95100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -111700000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 207400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -84200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 62100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 65700000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 2114600000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 114400000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisition, net of cash acquired",
              "value": 1074800000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sale of equity interest in Samsung Bioepis",
              "value": 406800000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from sale of priority review voucher",
              "value": 88600000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 179100000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 96700000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 4400000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": -780600000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 34800000
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 650000000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -6600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -691400000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 642600000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 6700000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-24-000025",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2024,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2024-01-01 00:00:00",
        "endDate": "2024-06-30 00:00:00",
        "filedDate": "2024-08-01 00:00:00",
        "acceptedDate": "2024-08-01 16:11:25",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1908900000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net of allowance for doubtful accounts of $2.5 and $2.4, respectively",
              "value": 2078200000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 2506100000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 615300000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7108500000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3249300000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 389400000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 8232900000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 6227400000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 915100000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 681500000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 26804100000
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of term loan",
              "value": 0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 281600000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 354500000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2472100000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3108200000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and term loan",
              "value": 6292000000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 590600000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 367500000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 556700000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10915000000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.000 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $\u2014 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 407500000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -146000000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 18604600000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 15889100000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 26804100000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 4755400000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1088200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 966800000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1135300000
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 165200000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit sharing/(loss reimbursement)",
              "value": 128000000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 18100000
            },
            {
              "concept": "us-gaap_GainLossOnDispositionOfIntangibleAssets",
              "unit": "usd",
              "label": "Gain on sale of priority review voucher, net",
              "value": 88600000.0
            },
            {
              "concept": "us-gaap_OtherOperatingIncomeExpenseNet",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": -178900000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 3591900000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
              "unit": "usd",
              "label": "Income before income tax (benefit) expense",
              "value": 1163500000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 186500000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 977000000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": 0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 977000000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 6
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 6
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 145400000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 145900000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 34800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -27000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 7700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 984700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 984700000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 977000000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 306400000
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 44400000
            },
            {
              "concept": "biib_AmortizationOfInventoryStepUp",
              "unit": "usd",
              "label": "Amortization of acquired inventory step-up",
              "value": 134200000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 143400000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -47100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -61600000
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of priority review voucher, net",
              "value": 88600000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -65000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 2800000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 188200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -115600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -7700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 103000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 1179000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 79400000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sale of equity interest in Samsung Bioepis",
              "value": 406800000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from sale of priority review voucher",
              "value": 103000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 84100000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 57500000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 3300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": 400500000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 40800000
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 650000000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 6000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -684800000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 894700000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -35700000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-24-000016",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2024,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2024-01-01 00:00:00",
        "endDate": "2024-03-31 00:00:00",
        "filedDate": "2024-04-24 00:00:00",
        "acceptedDate": "2024-04-24 16:15:22",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1074400000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectively",
              "value": 1999700000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 2516800000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 1165300000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 6756200000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3275300000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 428100000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 8284700000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 6227400000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 898300000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 697600000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 26567600000
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of term loan",
              "value": 250000000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 231200000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 387000000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2354600000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3222800000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and term loan",
              "value": 6290100000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 658100000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 406500000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 777100000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 11354600000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.000 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $\u2014 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 329500000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -160500000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 18021000000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 15213000000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 26567600000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 2290500000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 542200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 452900000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 581500000
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 78300000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit sharing/(loss reimbursement)",
              "value": 65600000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 11500000
            },
            {
              "concept": "us-gaap_OtherOperatingIncomeExpenseNet",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": -93700000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 1825700000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
              "unit": "usd",
              "label": "Income before income tax (benefit) expense",
              "value": 464800000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 71400000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 393400000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": 0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 393400000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 2
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 2
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 145200000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 145900000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 14700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -21400000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -6800000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 386600000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 386600000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 393400000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 147500000
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 27500000
            },
            {
              "concept": "biib_AmortizationOfInventoryStepUp",
              "unit": "usd",
              "label": "Amortization of inventory step-up",
              "value": 44100000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 72800000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 39900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -31300000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -25400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -84400000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 77700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -177100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -2200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 56100000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 553200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 45900000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 75000000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 55600000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 700000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": -66000000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 46900000
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings and premiums paid",
              "value": 400000000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 7300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -439600000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 47600000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -23100000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-23-000038",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2023,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2023-01-01 00:00:00",
        "endDate": "2023-09-30 00:00:00",
        "filedDate": "2023-11-08 00:00:00",
        "acceptedDate": "2023-11-08 16:35:26",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2287900000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 2209700000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 2982400000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 974100000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 8454100000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 100000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3301600000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 460900000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 7344600000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 6807500000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1069800000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 754600000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 28193200000
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of term loan",
              "value": 500000000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 243800000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 440100000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 3838400000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 5022300000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and term loan",
              "value": 6786400000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 728100000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 428800000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 747900000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 13713500000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 242200000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -159300000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 17377900000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 14483800000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -4100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 14479700000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 28193200000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 7449300000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1915100000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1891100000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1941200000
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 164000000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit sharing/(loss reimbursement)",
              "value": 164500000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 0.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 120000000
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of building",
              "value": 0.0
            },
            {
              "concept": "us-gaap_OtherOperatingIncomeExpenseNet",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": -248200000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 6444100000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income (loss) before income tax (benefit) expense and equity in loss of investee, net of tax",
              "value": 1005200000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 92600000
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income (loss)",
              "value": 912600000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": 1200000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income (loss) attributable to Biogen Inc.",
              "value": 911400000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings (loss) per share attributable to Biogen Inc.",
              "value": 6
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings (loss) per share attributable to Biogen Inc.",
              "value": 6
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings (loss) per share attributable to Biogen Inc.",
              "value": 144700000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings (loss) per share attributable to Biogen Inc.",
              "value": 145500000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 15700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 1100000
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -11800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 5600000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 917000000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 1200000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 918200000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 0.0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of building",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income (loss)",
              "value": 912600000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 354700000
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 62100000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 209300000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -377700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -275700000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investments",
              "value": 0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee",
              "unit": "usd",
              "label": "Gain on sale of equity interest in Samsung Bioepis",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -98600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 73400000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 34900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": 293900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -114800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 71400000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 1534700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 211800000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 7380800000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 5140700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisition of Reata, net of cash acquired",
              "value": 6335600000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sale of equity interest in Samsung Bioepis",
              "value": 788100000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 34400000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 106200000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 1300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": -3448700000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 48000000
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings and premiums paid",
              "value": 159900000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings, net",
              "value": 997200000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 4200000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 1900000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": 795400000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -1118600000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -12800000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-23-000030",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2023,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2023-01-01 00:00:00",
        "endDate": "2023-06-30 00:00:00",
        "filedDate": "2023-07-25 00:00:00",
        "acceptedDate": "2023-07-25 16:20:33",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2617800000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 3460500000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 2124000000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1333500000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 895900000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 10431700000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1208000000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3307200000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 366500000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1776400000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5753700000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1208400000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1104900000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 25156800000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 260000000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 445400000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2481100000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3186500000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 6284600000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 143900000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 304400000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 776900000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10696300000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 170700000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -172800000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 17446000000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 14466900000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -6400000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 14460500000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 25156800000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 4919000000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1255500000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1154800000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1153000000
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 103100000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit sharing/(loss reimbursement)",
              "value": 114000000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 0.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 44000000
            },
            {
              "concept": "us-gaap_OtherOperatingIncomeExpenseNet",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": 51800000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 3772600000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1146400000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 165500000
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 980900000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": 1400000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 979500000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 6
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 6
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 144600000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 145400000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 1200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -28500000
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 18700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -7900000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 971600000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 1400000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 973000000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 980900000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 229700000
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 36800000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 147100000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -170900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": 26800000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investments",
              "value": 0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee",
              "unit": "usd",
              "label": "Gain on sale of equity interest in Samsung Bioepis",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -60500000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -15100000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 65100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -127100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -82400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 55500000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 942300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 137600000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 1682200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 4120300000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sale of equity interest in Samsung Bioepis",
              "value": 788100000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 21000000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 103200000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 1100000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": -1706500000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 54600000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 1700000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -53200000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -817400000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 15900000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-23-000016",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2023,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2023-01-01 00:00:00",
        "endDate": "2023-03-31 00:00:00",
        "filedDate": "2023-04-25 00:00:00",
        "acceptedDate": "2023-04-25 16:21:24",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2898200000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2143100000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1634400000
            },
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 393800000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1281000000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 1412000000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 9762500000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 978200000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3300900000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 399100000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1813300000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5751800000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1211800000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1380800000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 24598400000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 235500000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 491200000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2288200000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3014900000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 6282700000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 251300000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 327000000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 935500000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10811400000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 91200000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -172000000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 16854400000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 13796600000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -9600000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 13787000000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 24598400000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 2463000000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 662800000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 570600000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 605000000
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 50200000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit sharing/(loss reimbursement)",
              "value": 57100000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 0.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 9600000.0
            },
            {
              "concept": "us-gaap_OtherOperatingIncomeExpenseNet",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": -69400000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 2024700000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 438300000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 50700000
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 387600000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": -300000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 387900000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 2
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 2
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 144400000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 145200000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 5700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -35400000
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 22100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -7100000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 380800000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -300000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 380500000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 387600000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 112300000
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 17400000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 75600000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -64500000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -79600000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investments",
              "value": 0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -31400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -77200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInDueFromRelatedParties",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": -37600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": -27900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -295000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 65000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 96800000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 455300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 66600000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 406700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1321200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 5000000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 33800000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 700000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": -953000000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 60100000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 200000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 16500000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -43400000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -541100000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 20000000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-22-000031",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2022,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2022-01-01 00:00:00",
        "endDate": "2022-09-30 00:00:00",
        "filedDate": "2022-10-25 00:00:00",
        "acceptedDate": "2022-10-25 16:11:18",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 3675600000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1235500000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1568800000
            },
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 415400000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1375000000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 1495500000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 9765800000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 860300000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3266400000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 424500000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 2008900000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5741200000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1174500000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1612600000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 24854200000
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 237300000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 383200000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 3305900000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3926400000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 6279200000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 328900000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 354800000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1198100000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 12087400000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -163600000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 15916100000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 12775500000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -8700000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 12766800000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 24854200000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 7629400000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1707400000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1629500000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1770800000
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 190900000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": -42600000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 13700000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 124100000.0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of building",
              "value": 503700000.0
            },
            {
              "concept": "us-gaap_OtherOperatingIncomeExpenseNet",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": 221300000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 4641400000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 2988000000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 578500000
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 2600000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2412100000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": -84400000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 2496500000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 17
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 17
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 145800000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 146200000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -19000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 79000000
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": -25500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -4200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -95600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -56900000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 2439600000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -84400000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 2355200000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 13700000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
              "unit": "usd",
              "label": "Gain on sale of building",
              "value": 503700000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2412100000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 398600000
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 321600000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 186900000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -139800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -160300000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investments",
              "value": 2600000
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfInvestments",
              "unit": "usd",
              "label": "Gain on sale of equity interest in Samsung Bioepis",
              "value": 1505400000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -147800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 109500000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInDueFromRelatedParties",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 3000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 338300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": 632300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -100200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -15900000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 1559300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 153900000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 3104700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 2805900000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sale of equity interest in Samsung Bioepis",
              "value": 990300000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from sale of building",
              "value": 582600000.0
            },
            {
              "concept": "us-gaap_ProceedsFromDivestitureOfBusinesses",
              "unit": "usd",
              "label": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 1900000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -1800000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": 1717700000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 750000000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 5800000
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings and premiums paid",
              "value": 1002200000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 12200000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 5900000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -1739900000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 1537100000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -122900000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-22-000025",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2022,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2022-01-01 00:00:00",
        "endDate": "2022-06-30 00:00:00",
        "filedDate": "2022-07-20 00:00:00",
        "acceptedDate": "2022-07-20 16:24:42",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2646600000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2151300000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1567600000.0
            },
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 435900000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1294200000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 1645300000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 9740900000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1102900000.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3355100000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 321100000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 2075300000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5749600000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1235700000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1500800000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 25081400000.0
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 999800000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 284900000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 434800000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 3298500000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 5018000000.0
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 6277400000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 480600000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 274200000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1167800000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 13218000000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -110400000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 14959900000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 11872500000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -9100000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 11863400000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 25081400000.0
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 5120900000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1237900000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1080300000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1207500000.0
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 134400000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": -87900000.0
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 11600000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 108700000.0
            },
            {
              "concept": "us-gaap_OtherOperatingIncomeExpenseNet",
              "unit": "usd",
              "label": "Other (income) expense, net",
              "value": 165300000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 3504000000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1616900000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 342300000.0
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 2600000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1277200000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": -84600000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 1361800000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 9.3
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 9.27
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 146500000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 146800000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -18000000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 73100000.0
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": -25500000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -2700000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -36000000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -3700000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 1358100000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -84600000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 1273500000.0
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 11600000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1277200000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 277900000.0
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 0.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 305600000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 123300000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -47500000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -269300000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investments",
              "value": 2600000.0
            },
            {
              "concept": "us-gaap_GainLossOnSaleOfInvestments",
              "unit": "usd",
              "label": "Gain on sale of equity interest in Samsung Bioepis",
              "value": 1505400000.0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -112200000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 67300000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInDueFromRelatedParties",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 23600000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 243300000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": 634000000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -65900000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 134000000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 898300000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 94800000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 1461500000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 2311600000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from sale of equity in Samsung Bioepis",
              "value": 990300000.0
            },
            {
              "concept": "us-gaap_ProceedsFromDivestitureOfBusinesses",
              "unit": "usd",
              "label": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 1900000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from the sales of strategic investments",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -2000000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": 45500000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 500000000.0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 11500000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings and premiums paid on debt exchange",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 12100000.0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 11400000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -488000000.0
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 455800000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -70600000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-22-000016",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2022,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2022-01-01 00:00:00",
        "endDate": "2022-03-31 00:00:00",
        "filedDate": "2022-05-03 00:00:00",
        "acceptedDate": "2022-05-03 16:16:45",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1749300000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2002400000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1632000000.0
            },
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 389400000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1215400000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 927400000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7915900000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1001600000.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3372800000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 359000000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 2150800000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5758000000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1288800000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1767500000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 23614400000.0
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 999500000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 317300000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 398700000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2231100000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3946600000.0
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 6275700000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 571200000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 312300000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1287900000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 12393700000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 119000000.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -115200000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 14215500000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 11242300000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -21600000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 11220700000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 23614400000.0
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 2531800000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 753900000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 551700000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 634900000.0
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 66900000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": -117300000.0
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 7100000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 38100000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 1921100000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 610700000.0
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -263300000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 347400000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": 125600000.0
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": -3300000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 218500000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": -85300000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 303800000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 2.06
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 2.06
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 147100000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 147600000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -9700000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 15900000.0
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges, net of tax",
              "value": 6200000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -900000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -21800000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -8500000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to Biogen Inc.",
              "value": 295300000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -85300000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 210000000.0
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 7100000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 218500000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 143100000.0
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 0.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Excess and obsolescence charges related to inventory",
              "value": 281500000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 67600000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 1000000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -191100000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investments",
              "value": -3300000.0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -43300000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 87500000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInDueFromRelatedParties",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": -22900000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 142600000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -461600000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 101900000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 213600000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) operating activities",
              "value": 161800000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 57900000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 543600000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1133500000.0
            },
            {
              "concept": "us-gaap_ProceedsFromDivestitureOfBusinesses",
              "unit": "usd",
              "label": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from the sales of strategic investments",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 200000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) investing activities",
              "value": -648000000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 20800000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings and premiums paid on debt exchange",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net (distribution) contribution to noncontrolling interest",
              "value": 200000.0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 4100000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by (used in) financing activities",
              "value": -16500000.0
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -502700000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -9400000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-21-000052",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2021,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2021-01-01 00:00:00",
        "endDate": "2021-09-30 00:00:00",
        "filedDate": "2021-10-20 00:00:00",
        "acceptedDate": "2021-10-20 16:19:52",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1541800000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1413300000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1723000000.0
            },
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 400000000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1347900000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 736300000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7162300000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 968300000.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3410700000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 389100000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 2286800000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5760500000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1810400000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 2018600000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 23806700000.0
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 998800000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 234200000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 427900000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2550700000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 4211600000.0
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 6272300000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 774700000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 348200000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1318200000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 12925000000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -136600000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 13543500000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 10429900000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 451800000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 10881700000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 23806700000.0
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 8247900000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1449600000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1801700000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1886400000.0
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 813200000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 74500000.0
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 49100000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 18000000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 5994300000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 2253600000.0
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -913400000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1340200000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": -390700000.0
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 17200000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1748100000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": 560200000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 1187900000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 7.93
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 7.9
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 149900000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 150300000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -1400000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 205000000.0
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges",
              "value": 35200000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -3900000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -80300000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 162400000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 1350300000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 560800000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 1911100000.0
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 49100000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 18000000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1748100000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 353000000.0
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 629300000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 179800000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -750100000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -710500000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "(Gain) loss on equity method investment",
              "value": 17200000.0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -201000000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -157800000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInDueFromRelatedParties",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": -13500000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 322600000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -243300000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 260500000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 87600000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by operating activities",
              "value": 2801600000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 206500000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 2028100000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 2372600000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
              "unit": "usd",
              "label": "Payments subsidiary and affiliates stock",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 28100000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 18000000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 1900000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 91200000.0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -600000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow used in investing activities",
              "value": -451000000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 1800000000.0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 8300000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayment of borrowings and premiums paid on debt exchange",
              "value": 170000000.0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 0.0
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities",
              "unit": "usd",
              "label": "Cash proceeds from settlement of swap",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net distribution to noncontrolling interest",
              "value": 94800000.0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -22900000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow used in financing activities",
              "value": -2096000000.0
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 254600000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -44000000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-21-000044",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2021,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2021-01-01 00:00:00",
        "endDate": "2021-06-30 00:00:00",
        "filedDate": "2021-07-22 00:00:00",
        "acceptedDate": "2021-07-22 16:16:10",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1742000000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1308800000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1688000000.0
            },
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 422200000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1254800000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 767900000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7183700000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 915100000.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3442200000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 402500000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 2385000000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5763900000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1849900000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 2528100000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 24470400000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 230900000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 375300000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expense and other",
              "value": 2741000000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3347200000.0
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 7269200000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 918900000.0
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 363900000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1356400000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 13255600000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -171800000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 13900700000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 10751900000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 462900000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 11214800000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 24470400000.0
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenue",
              "value": 5469000000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 937800000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1099300000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1232300000.0
            },
            {
              "concept": "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 702200000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 53300000.0
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 33500000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 18000000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expense",
              "value": 4009400000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 1459600000.0
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -410500000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1049100000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax (benefit) expense",
              "value": -364900000.0
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": 16100000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1430100000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": 571400000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 858700000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 5.7
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 5.68
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 150800000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 151200000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -1300000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 138600000.0
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges",
              "value": 20100000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -2400000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -32600000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 127200000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 985900000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 572000000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 1557900000.0
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 33500000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 18000000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1430100000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 219800000.0
            },
            {
              "concept": "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
              "unit": "usd",
              "label": "Impairment of intangible assets",
              "value": 585900000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 124100000.0
            },
            {
              "concept": "us-gaap_GainLossOnDerivativeInstrumentsNetPretax",
              "unit": "usd",
              "label": "Gain on interest rate swap",
              "value": 0.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -622800000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "(Gain) loss on strategic investments",
              "value": -283600000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Loss on equity method investment",
              "value": 16100000.0
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -112400000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -211500000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInDueFromRelatedParties",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 8700000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 193800000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expense and other current liabilities",
              "value": -188400000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 171500000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 97300000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flow provided by operating activities",
              "value": 1996300000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 1452700000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1626900000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
              "unit": "usd",
              "label": "Purchase of Sangamo Therapeutics, Inc. stock",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 28100000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 164500000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 91200000.0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -2000000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flow used in investing activities",
              "value": -217400000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 1050000000.0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 14200000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayment of borrowings and premiums paid on debt exchange",
              "value": 170000000.0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 0.0
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities",
              "unit": "usd",
              "label": "Cash proceeds from settlement of swap",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net distribution to noncontrolling interest",
              "value": 94800000.0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -20500000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flow used in financing activities",
              "value": -1349500000.0
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 429400000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -18600000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-21-000028",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2021,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2021-01-01 00:00:00",
        "endDate": "2021-03-31 00:00:00",
        "filedDate": "2021-04-22 00:00:00",
        "acceptedDate": "2021-04-22 16:14:39",
        "report": {
          "bs": [
            {
              "label": "Net increase (decrease) in cash and cash equivalents",
              "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "value": 1217500000.0
            },
            {
              "label": "Marketable securities",
              "concept": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "value": 1320000000.0
            },
            {
              "label": "Accounts receivable, net",
              "concept": "AccountsReceivableNetCurrent",
              "unit": "usd",
              "value": 1854300000.0
            },
            {
              "label": "Due from anti-CD20 therapeutic programs",
              "concept": "biib:DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "value": 369800000.0
            },
            {
              "label": "Inventory",
              "concept": "InventoryNet",
              "unit": "usd",
              "value": 1171800000.0
            },
            {
              "label": "Other current assets",
              "concept": "OtherAssetsCurrent",
              "unit": "usd",
              "value": 786100000.0
            },
            {
              "label": "Current assets:",
              "concept": "AssetsCurrent",
              "unit": "usd",
              "value": 6719500000.0
            },
            {
              "label": "Marketable securities",
              "concept": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "value": 821900000.0
            },
            {
              "label": "Property, plant and equipment, net",
              "concept": "PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "value": 3438300000.0
            },
            {
              "label": "Operating lease assets",
              "concept": "OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "value": 414500000.0
            },
            {
              "label": "Intangible assets, net",
              "concept": "IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "value": 2988100000.0
            },
            {
              "label": "Summary of roll forward of the changes in goodwill",
              "concept": "Goodwill",
              "unit": "usd",
              "value": 5763100000.0
            },
            {
              "label": "Deferred tax asset",
              "concept": "DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "value": 1286300000.0
            },
            {
              "label": "Investments and other assets",
              "concept": "OtherAssetsNoncurrent",
              "unit": "usd",
              "value": 2423000000.0
            },
            {
              "label": "ASSETS",
              "concept": "Assets",
              "unit": "usd",
              "value": 23854700000.0
            },
            {
              "label": "Taxes payable",
              "concept": "TaxesPayableCurrent",
              "unit": "usd",
              "value": 143100000.0
            },
            {
              "label": "Accounts payable",
              "concept": "AccountsPayableCurrent",
              "unit": "usd",
              "value": 430400000.0
            },
            {
              "label": "Accrued expense and other",
              "concept": "OtherLiabilitiesCurrent",
              "unit": "usd",
              "value": 2592300000.0
            },
            {
              "label": "Total current liabilities",
              "concept": "LiabilitiesCurrent",
              "unit": "usd",
              "value": 3165800000.0
            },
            {
              "label": "Notes payable",
              "concept": "LongTermDebt",
              "unit": "usd",
              "value": 7267200000.0
            },
            {
              "label": "Deferred tax liability",
              "concept": "DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "value": 966700000.0
            },
            {
              "label": "Long-term operating lease liabilities",
              "concept": "OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "value": 380000000.0
            },
            {
              "label": "Other long-term liabilities",
              "concept": "OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "value": 1411800000.0
            },
            {
              "label": "LIABILITIES AND EQUITY",
              "concept": "Liabilities",
              "unit": "usd",
              "value": 13191500000.0
            },
            {
              "label": "Commitments and contingencies",
              "concept": "CommitmentsAndContingencies",
              "unit": "usd",
              "value": "N/A"
            },
            {
              "label": "Preferred stock, par value $0.001 per share",
              "concept": "PreferredStockValue",
              "unit": "usd",
              "value": "N/A"
            },
            {
              "label": "Common stock, par value $0.0005 per share",
              "concept": "CommonStockValue",
              "unit": "usd",
              "value": 100000.0
            },
            {
              "label": "Additional paid-in capital",
              "concept": "AdditionalPaidInCapital",
              "unit": "usd",
              "value": "N/A"
            },
            {
              "label": "Accumulated other comprehensive loss",
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "value": -174300000.0
            },
            {
              "label": "Retained earnings",
              "concept": "RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "value": 13833500000.0
            },
            {
              "label": "Repurchase of common stock, at cost",
              "concept": "TreasuryStockValue",
              "unit": "usd",
              "value": 2977100000.0
            },
            {
              "label": "Equity:",
              "concept": "StockholdersEquity",
              "unit": "usd",
              "value": 10682200000.0
            },
            {
              "label": "Noncontrolling interests",
              "concept": "MinorityInterest",
              "unit": "usd",
              "value": -19000000.0
            },
            {
              "label": "Equity:",
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "value": 10663200000.0
            },
            {
              "label": "LIABILITIES AND EQUITY",
              "concept": "LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "value": 23854700000.0
            }
          ],
          "cf": [
            {
              "label": "Net income",
              "concept": "ProfitLoss",
              "unit": "usd",
              "value": 404600000.0
            },
            {
              "label": "Depreciation, amortization and impairments",
              "concept": "DepreciationDepletionAndAmortization",
              "unit": "usd",
              "value": 146900000.0
            },
            {
              "label": "Acquired in-process research and development",
              "concept": "ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "value": "N/A"
            },
            {
              "label": "Share-based compensation",
              "concept": "ShareBasedCompensation",
              "unit": "usd",
              "value": 70000000.0
            },
            {
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "concept": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "value": 33800000.0
            },
            {
              "label": "Deferred income taxes",
              "concept": "DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "value": -15000000.0
            },
            {
              "label": "(Gain) loss on strategic investments",
              "concept": "IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "value": -437600000.0
            },
            {
              "label": "Our share of Samsung Bioepis gains (losses)",
              "concept": "IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "value": -18200000.0
            },
            {
              "label": "Other",
              "concept": "OtherNoncashIncomeExpense",
              "unit": "usd",
              "value": -71700000.0
            },
            {
              "label": "Accounts receivable",
              "concept": "IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "value": -37200000.0
            },
            {
              "label": "Due from anti-CD20 therapeutic programs",
              "concept": "IncreaseDecreaseInDueFromRelatedParties",
              "unit": "usd",
              "value": -43800000.0
            },
            {
              "label": "Inventory",
              "concept": "IncreaseDecreaseInInventories",
              "unit": "usd",
              "value": 112500000.0
            },
            {
              "label": "Accrued expense and other current liabilities",
              "concept": "IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "value": -283600000.0
            },
            {
              "label": "Income tax assets and liabilities",
              "concept": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "value": 64800000.0
            },
            {
              "label": "Other changes in operating assets and liabilities, net",
              "concept": "IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "value": 80900000.0
            },
            {
              "label": "Net cash flow provided by operating activities",
              "concept": "NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "value": 769000000.0
            },
            {
              "label": "Proceeds from sales and maturities of marketable securities",
              "concept": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "value": 819200000.0
            },
            {
              "label": "Purchases of marketable securities",
              "concept": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "value": 913300000.0
            },
            {
              "label": "Proceeds from divestiture of Hilleru00f8d, Denmark manufacturing operations",
              "concept": "ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "value": 28100000.0
            },
            {
              "label": "Purchases of property, plant and equipment",
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "value": 92600000.0
            },
            {
              "label": "Acquired in-process research and development",
              "concept": "PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "value": "N/A"
            },
            {
              "label": "Acquisitions of intangible assets",
              "concept": "PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "value": "N/A"
            },
            {
              "label": "Proceeds from sales of strategic investments",
              "concept": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
              "unit": "usd",
              "value": 91200000.0
            },
            {
              "label": "Other",
              "concept": "PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "value": -2700000.0
            },
            {
              "label": "Cash flows from investing activities:",
              "concept": "NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "value": -64700000.0
            },
            {
              "label": "Purchases of treasury stock",
              "concept": "PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "value": 600000000.0
            },
            {
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "concept": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "value": 27100000.0
            },
            {
              "label": "Repayments of borrowings and premiums paid on debt exchange",
              "concept": "RepaymentsOfDebt",
              "unit": "usd",
              "value": 169300000.0
            },
            {
              "label": "Other",
              "concept": "ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "value": 11400000.0
            },
            {
              "label": "Cash flows from financing activities:",
              "concept": "NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "value": -785000000.0
            },
            {
              "label": "Net increase (decrease) in cash and cash equivalents",
              "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "value": -80700000.0
            },
            {
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "value": -33000000.0
            }
          ],
          "ic": [
            {
              "label": "Total revenue",
              "concept": "Revenues",
              "unit": "usd",
              "value": 2694000000.0
            },
            {
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "concept": "CostOfGoodsAndServicesSold",
              "unit": "usd",
              "value": 478100000.0
            },
            {
              "label": "Research and development",
              "concept": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "value": 514200000.00000006
            },
            {
              "label": "Selling, general and administrative",
              "concept": "SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "value": 595000000.0
            },
            {
              "label": "Amortization and impairment of acquired intangible assets",
              "concept": "biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets",
              "unit": "usd",
              "value": 98100000.0
            },
            {
              "label": "Collaboration profit (loss) sharing",
              "concept": "biib:Collaborationprofitlosssharing",
              "unit": "usd",
              "value": 68500000.0
            },
            {
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "concept": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "value": 33800000.0
            },
            {
              "label": "Acquired in-process research and development",
              "concept": "ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "value": "N/A"
            },
            {
              "label": "Total cost and expense",
              "concept": "CostsAndExpenses",
              "unit": "usd",
              "value": 1720100000.0
            },
            {
              "label": "Income from operations",
              "concept": "OperatingIncomeLoss",
              "unit": "usd",
              "value": 973900000.0
            },
            {
              "label": "Other income (expense), net",
              "concept": "NonoperatingIncomeExpense",
              "unit": "usd",
              "value": -506900000.0
            },
            {
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "value": 467000000.0
            },
            {
              "label": "Income tax expense",
              "concept": "IncomeTaxExpenseBenefit",
              "unit": "usd",
              "value": 44200000.0
            },
            {
              "label": "Equity in (income) loss of investee, net of tax",
              "concept": "biib:IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "value": -18200000.0
            },
            {
              "label": "Net income",
              "concept": "ProfitLoss",
              "unit": "usd",
              "value": 404600000.0
            },
            {
              "label": "Netu00a0income (loss) attributable to noncontrolling interests, netu00a0ofu00a0tax",
              "concept": "NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "value": -5600000.0
            },
            {
              "label": "Netu00a0income (loss) attributable to noncontrolling interests, netu00a0ofu00a0tax",
              "concept": "NetIncomeLoss",
              "unit": "usd",
              "value": 410200000.0
            },
            {
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "concept": "EarningsPerShareBasic",
              "unit": "usd/shares",
              "value": 2.7
            },
            {
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "concept": "EarningsPerShareDiluted",
              "unit": "usd/shares",
              "value": 2.69
            },
            {
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "value": 151900000.0
            },
            {
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "value": 152300000.0
            },
            {
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "concept": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "value": -800000.0
            },
            {
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "concept": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "value": 149600000.0
            },
            {
              "label": "Gains (losses) on net investment hedges",
              "concept": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "value": 22400000.0
            },
            {
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "concept": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "value": -2000000.0
            },
            {
              "label": "Currency translation adjustment",
              "concept": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "value": -48500000.0
            },
            {
              "label": "Other comprehensive income:",
              "concept": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "value": 124700000.0
            },
            {
              "label": "Comprehensive income attributable to Biogen Inc.",
              "concept": "ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "value": 534900000.0
            },
            {
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "value": -4900000.0
            },
            {
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "value": 530000000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-20-000036",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2020,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2020-01-01 00:00:00",
        "endDate": "2020-09-30 00:00:00",
        "filedDate": "2020-10-21 00:00:00",
        "acceptedDate": "2020-10-21 17:16:30",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2224800000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1355000000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 2024900000
            },
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 527200000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1027700000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 683500000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7843100000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1009800000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3359900000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 434200000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3323600000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5755700000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1372900000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1834900000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 24934100000
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 119400000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 398400000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 3286200000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3804000000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 7425000000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 1123400000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 409100000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1428100000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 14189600000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -225500000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 13961000000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 10758500000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -14000000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 10744500000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 24934100000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 10592000000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1314600000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 2264800000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1698300000
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 166500000
            },
            {
              "concept": "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
              "unit": "usd",
              "label": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 23500000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 5711300000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 4880700000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -186100000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 4694600000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 979000000
            },
            {
              "concept": "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax",
              "unit": "usd",
              "label": "Equity in (income) loss of investee, net of tax",
              "value": -12700000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 3702900000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
              "value": 60200000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 3642700000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 22
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 22
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 163400000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 163700000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 1000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -101100000
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges",
              "value": 5500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -400000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 3900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -90300000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 3552400000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 61100000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 3613500000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 196300000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 23500000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 3702900000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation, amortization and impairments",
              "value": 366800000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 149300000
            },
            {
              "concept": "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
              "unit": "usd",
              "label": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 211900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "Unrealized (gain) loss on strategic investments",
              "value": -41800000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Loss on equity method investment",
              "value": 14700000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -110100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 135700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInDueFromRelatedParties",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": -63000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 270600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 372900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 15300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 97000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 4596900000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 5240700000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 4649100000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisition of Nightstar Therapeutics plc, net of cash acquired",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
              "unit": "usd",
              "label": "Purchase of Sangamo Therapeutics, Inc. stock",
              "value": 565500000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 338800000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 37000000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 500000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 18000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) investing activities",
              "value": -442200000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 6279100000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 11800000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 2967300000
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 1500000000
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net distribution to noncontrolling interest",
              "value": 70900000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 22900000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -4871600000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -716900000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 28000000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-20-000022",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2020,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2020-01-01 00:00:00",
        "endDate": "2020-06-30 00:00:00",
        "filedDate": "2020-07-22 00:00:00",
        "acceptedDate": "2020-07-22 16:37:51",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2384900000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1942700000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 2133600000
            },
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 441100000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 952700000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 638800000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 8493800000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 922800000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3330700000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 436200000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3383800000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5751000000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxAssetsNet",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 1710200000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1483300000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 25511800000
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 576700000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 383900000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2486500000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3447100000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 7423800000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 1461500000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 414800000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1475400000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 14222600000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss), net of tax ending balance",
              "value": -181000000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 14466700000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 11308700000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -19500000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Ending balance",
              "value": 11289200000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 25511800000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues from anti-CD20 therapeutic programs",
              "value": 7215900000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 865500000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1123900000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1125200000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 133000000
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 93500000
            },
            {
              "concept": "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
              "unit": "usd",
              "label": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Contingent consideration",
              "value": -5500000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 3421600000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 3794300000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Total other income (expense), net",
              "value": -57500000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 3736800000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 738200000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Our share of Samsung Bioepis gains (losses)",
              "value": 400000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2999000000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 57800000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 2941200000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 17
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 17
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 166700000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 167000000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -17400000
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges",
              "value": 16800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -47000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -45800000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 2895400000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -59600000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 2955000000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Contingent consideration",
              "value": -5500000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2999000000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation, amortization and impairments",
              "value": 232800000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 115800000
            },
            {
              "concept": "us-gaap_GainLossOnDerivativeInstrumentsNetPretax",
              "unit": "usd",
              "label": "Gain on interest rate swap",
              "value": 3300000
            },
            {
              "concept": "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
              "unit": "usd",
              "label": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 180200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "Unrealized (gain) loss on strategic investments",
              "value": 39700000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -85300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 268800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInDueFromRelatedParties",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": -149100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 188200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -441400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 504600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -9900000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 3415800000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 3879900000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 3753900000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisition of Nightstar Therapeutics plc, net of cash acquired",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
              "unit": "usd",
              "label": "Purchase of Sangamo Therapeutics, Inc. stock",
              "value": 141800000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 254700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 37000000
            },
            {
              "concept": "us-gaap_ProceedsFromHedgeInvestingActivities",
              "unit": "usd",
              "label": "Proceeds from settlement of net investment hedge",
              "value": -7800000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
              "unit": "usd",
              "label": "Proceeds from sale of available-for-sale securities, equity",
              "value": 500000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by investing activities",
              "value": -389800000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Payments for repurchase of common stock",
              "value": 5029100000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 19200000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 2967300000
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 1500000000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities",
              "unit": "usd",
              "label": "Cash proceeds from settlement of swap",
              "value": -3300000
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Payments to Noncontrolling Interests",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 19000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -3558700000
            },
            {
              "concept": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -532700000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 3900000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-20-000011",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2020,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2020-01-01 00:00:00",
        "endDate": "2020-03-31 00:00:00",
        "filedDate": "2020-04-23 00:00:00",
        "acceptedDate": "2020-04-23 16:15:49",
        "report": {
          "bs": [
            {
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 2591300000,
              "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1269100000,
              "concept": "AvailableForSaleSecuritiesDebtSecuritiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 2092600000,
              "concept": "AccountsReceivableNetCurrent"
            },
            {
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 511600000,
              "concept": "biib:DuefromantiCD20therapeuticprograms"
            },
            {
              "unit": "usd",
              "label": "Components of inventories",
              "value": 858800000,
              "concept": "InventoryNet"
            },
            {
              "unit": "usd",
              "label": "Other current assets",
              "value": 683800000,
              "concept": "OtherAssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Current assets:",
              "value": 8007200000,
              "concept": "AssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 969500000,
              "concept": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3281600000,
              "concept": "PropertyPlantAndEquipmentNet"
            },
            {
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 422000000,
              "concept": "OperatingLeaseRightOfUseAsset"
            },
            {
              "unit": "usd",
              "label": "Intangible assets",
              "value": 3446900000,
              "concept": "IntangibleAssetsNetExcludingGoodwill"
            },
            {
              "unit": "usd",
              "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
              "value": 5752000000,
              "concept": "Goodwill"
            },
            {
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 3109400000,
              "concept": "DeferredIncomeTaxAssetsNet"
            },
            {
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1130600000,
              "concept": "OtherAssetsNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Assets:",
              "value": 26119200000,
              "concept": "Assets"
            },
            {
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 1501800000,
              "concept": "NotesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Taxes payable",
              "value": 310000000,
              "concept": "TaxesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts payable",
              "value": 389000000,
              "concept": "AccountsPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 2437800000,
              "concept": "OtherLiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current liabilities:",
              "value": 4638600000,
              "concept": "LiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Notes payable",
              "value": 4459900000,
              "concept": "LongTermDebt"
            },
            {
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 2722800000,
              "concept": "DeferredIncomeTaxLiabilitiesNet"
            },
            {
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 403700000,
              "concept": "OperatingLeaseLiabilityNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1357300000,
              "concept": "OtherLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Liabilities:",
              "value": 13582300000,
              "concept": "Liabilities"
            },
            {
              "unit": "usd",
              "label": "Commitments and contingencies",
              "value": "N/A",
              "concept": "CommitmentsAndContingencies"
            },
            {
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": "N/A",
              "concept": "PreferredStockValue"
            },
            {
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000,
              "concept": "CommonStockValue"
            },
            {
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 100000,
              "concept": "AdditionalPaidInCapital"
            },
            {
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss), net of tax beginning balance",
              "value": -149300000,
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Retained earnings",
              "value": 15673100000,
              "concept": "RetainedEarningsAccumulatedDeficit"
            },
            {
              "unit": "usd",
              "label": "Repurchase of common stock, at cost",
              "value": 2977100000,
              "concept": "TreasuryStockValue"
            },
            {
              "unit": "usd",
              "label": "Beginning balance",
              "value": 12546900000,
              "concept": "StockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "Beginning balance",
              "value": -10000000,
              "concept": "MinorityInterest"
            },
            {
              "unit": "usd",
              "label": "Beginning balance",
              "value": 12536900000,
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 26119200000,
              "concept": "LiabilitiesAndStockholdersEquity"
            }
          ],
          "cf": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1392600000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Depreciation, amortization and impairments",
              "value": 119900000,
              "concept": "DepreciationDepletionAndAmortization"
            },
            {
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000,
              "concept": "ResearchAndDevelopmentInProcess"
            },
            {
              "unit": "usd",
              "label": "Share-based Compensation Expense included in consolidated statements of income",
              "value": 67700000,
              "concept": "ShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 4600000,
              "concept": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"
            },
            {
              "unit": "usd",
              "label": "Loss on divestiture of Hilleru00f8d, Denmark manufacturing operations",
              "value": "N/A",
              "concept": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax"
            },
            {
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 36900000,
              "concept": "DeferredIncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Unrealized (gain) loss on strategic investments",
              "value": -62000000,
              "concept": "IncreaseDecreaseInEquitySecuritiesFvNi"
            },
            {
              "unit": "usd",
              "label": "Loss recorded on Samsung Bioepis joint venture",
              "value": "N/A",
              "concept": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": -45700000,
              "concept": "OtherNoncashIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 238400000,
              "concept": "IncreaseDecreaseInAccountsReceivable"
            },
            {
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": -78600000,
              "concept": "IncreaseDecreaseInDueFromRelatedParties"
            },
            {
              "unit": "usd",
              "label": "Inventory",
              "value": 62200000,
              "concept": "IncreaseDecreaseInInventories"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -347400000,
              "concept": "IncreaseDecreaseInAccruedLiabilities"
            },
            {
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 223000000,
              "concept": "IncreaseDecreaseInAccruedIncomeTaxesPayable"
            },
            {
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -18500000,
              "concept": "IncreaseDecreaseInOtherOperatingCapitalNet"
            },
            {
              "unit": "usd",
              "label": "Cash flows from operating activities:",
              "value": 1467300000,
              "concept": "NetCashProvidedByUsedInOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 2389300000,
              "concept": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"
            },
            {
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1684700000,
              "concept": "PaymentsToAcquireAvailableForSaleSecuritiesDebt"
            },
            {
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": "N/A",
              "concept": "PaymentsToAcquireOtherProductiveAssets"
            },
            {
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 149700000,
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000,
              "concept": "PaymentsToAcquireInProcessResearchAndDevelopment"
            },
            {
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 37000000,
              "concept": "PaymentsToAcquireIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 500000,
              "concept": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 500000,
              "concept": "PaymentsForProceedsFromOtherInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from investing activities:",
              "value": 442900000,
              "concept": "NetCashProvidedByUsedInInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 2220200000,
              "concept": "PaymentsForRepurchaseOfCommonStock"
            },
            {
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 29600000,
              "concept": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 4500000,
              "concept": "ProceedsFromPaymentsForOtherFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from financing activities:",
              "value": -2245300000,
              "concept": "NetCashProvidedByUsedInFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -335100000,
              "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"
            },
            {
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 12700000,
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents"
            }
          ],
          "ic": [
            {
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 1399100000,
              "concept": "NetIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -7800000,
              "concept": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 33800000,
              "concept": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges",
              "value": 23000000,
              "concept": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -800000,
              "concept": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -63900000,
              "concept": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Other comprehensive income (loss), net of tax",
              "value": -14100000,
              "concept": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1385000000,
              "concept": "ComprehensiveIncomeNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -5900000,
              "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 1379100000,
              "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Total revenues",
              "value": 3534300000,
              "concept": "Revenues"
            },
            {
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 454300000,
              "concept": "CostOfGoodsAndServicesSold"
            },
            {
              "unit": "usd",
              "label": "Research and development",
              "value": 476300000,
              "concept": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"
            },
            {
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 570100000,
              "concept": "SellingGeneralAndAdministrativeExpense"
            },
            {
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 71500000,
              "concept": "AmortizationOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 71800000,
              "concept": "biib:Collaborationprofitlosssharing"
            },
            {
              "unit": "usd",
              "label": "Loss on divestiture of Hilleru00f8d, Denmark manufacturing operations",
              "value": "N/A",
              "concept": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"
            },
            {
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 4600000,
              "concept": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"
            },
            {
              "unit": "usd",
              "label": "Restructuring charges",
              "value": "N/A",
              "concept": "RestructuringCharges"
            },
            {
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 75000000,
              "concept": "ResearchAndDevelopmentInProcess"
            },
            {
              "unit": "usd",
              "label": "Cost and expenses:",
              "value": 1714400000,
              "concept": "CostsAndExpenses"
            },
            {
              "unit": "usd",
              "label": "Income from operations",
              "value": 1819900000,
              "concept": "OperatingIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -120500000,
              "concept": "NonoperatingIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1699400000,
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Income tax expense",
              "value": 292000000,
              "concept": "IncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": -14800000,
              "concept": "IncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1392600000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": -6500000,
              "concept": "NetIncomeLossAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd/shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 8.1,
              "concept": "EarningsPerShareBasic"
            },
            {
              "unit": "usd/shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 8.08,
              "concept": "EarningsPerShareDiluted"
            },
            {
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 172800000,
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic"
            },
            {
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 173100000,
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding"
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-19-000041",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2019,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2019-01-01 00:00:00",
        "endDate": "2019-09-30 00:00:00",
        "filedDate": "2019-10-22 00:00:00",
        "acceptedDate": "2019-10-22 16:12:44",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the period",
              "value": 2343900000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2093500000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1933500000
            },
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 582300000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory, current",
              "value": 751800000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 743200000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 8448200000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1813900000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3138100000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 422000000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3392400000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 5746100000.0
            },
            {
              "concept": "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 3284500000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1238800000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 27484000000
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 1495300000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 125600000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 382200000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 2429100000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 4432200000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 4458200000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 2820400000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 410500000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1370900000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 13492200000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss), net of tax ending balance",
              "value": -92300000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 17065200000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Ending balance",
              "value": 13995900000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Ending balance",
              "value": -4100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Ending balance",
              "value": 13991800000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 27484000000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Product revenues",
              "value": 10706600000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1508300000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1588900000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1709800000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 422200000.0
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 181800000
            },
            {
              "concept": "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
              "unit": "usd",
              "label": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": 95500000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 66300000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 1500000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 5441700000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 5264900000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Nonoperating Income (Expense)",
              "value": 132600000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 5397500000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 881900000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Our share of Samsung Bioepis gains (losses)",
              "value": -66800000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 4448800000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 4448800000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 23
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 23
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 190300000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 190500000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 10300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 38100000
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges",
              "value": 46900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -1500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 51300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 148100000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 4596900000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 400000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 4596500000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 66300000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 4448800000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation, amortization and impairments",
              "value": 567600000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 143900000
            },
            {
              "concept": "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
              "unit": "usd",
              "label": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
              "value": -95500000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 28400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "Unrealized (gain) loss on strategic investments",
              "value": 189800000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
              "unit": "usd",
              "label": "Loss recorded on Samsung Bioepis joint venture",
              "value": -63500000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -87400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 2400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": -47300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -109100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 64600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 61000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 5118400000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 3867600000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 4052100000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": 300000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisition of Nightstar Therapeutics plc, net of cash acquired",
              "value": 744400000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Proceeds from Sale of Property, Plant, and Equipment",
              "value": 923700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 404100000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Purchase of Ionis Pharmaceuticals, Inc. stock",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 476000000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 4600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -237900000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Payments for repurchase of common stock",
              "value": 3775200000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 16900000
            },
            {
              "concept": "us-gaap_RepaymentsOfLongTermDebt",
              "unit": "usd",
              "label": "Repayments of Long-term Debt",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net distribution to noncontrolling interest",
              "value": -4300000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 43800000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -3744000000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 1136500000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -17200000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-19-000029",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2019,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2019-01-01 00:00:00",
        "endDate": "2019-06-30 00:00:00",
        "filedDate": "2019-07-24 00:00:00",
        "acceptedDate": "2019-07-23 17:47:07",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1723400000.0
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1228800000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1959600000
            },
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 557500000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 776700000.0
            },
            {
              "concept": "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
              "unit": "usd",
              "label": "Assets held for sale",
              "value": 683400000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 980400000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7909800000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1309300000
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3077500000
            },
            {
              "concept": "us-gaap_OperatingLeaseRightOfUseAsset",
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 434400000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3681300000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 5749200000.0
            },
            {
              "concept": "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent",
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 2820100000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1306000000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 26287600000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 427200000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 377100000
            },
            {
              "concept": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
              "unit": "usd",
              "label": "Liabilities held for sale",
              "value": 88600000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2318000000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3210900000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 5948500000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 2400600000
            },
            {
              "concept": "us-gaap_OperatingLeaseLiabilityNoncurrent",
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 423000000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1355800000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 13338800000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss), net of tax ending balance",
              "value": -252900000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 16182800000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 12952900000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -4100000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 12948800000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 26287600000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Product revenues",
              "value": 7106500000.0
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 1078300000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1048500000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1155300000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 138300000
            },
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 121600000
            },
            {
              "concept": "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
              "unit": "usd",
              "label": "Loss on assets and liabilities held for sale",
              "value": 113200000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Contingent consideration",
              "value": 8500000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 1200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 3647900000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 3458600000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Nonoperating Income (Expense)",
              "value": 159900000.0
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 3618500000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income Tax Expense (Benefit)",
              "value": 670600000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Our share of Samsung Bioepis gains (losses)",
              "value": -45000000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2902900000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 2902900000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 15
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 14
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 193400000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 193700000.0
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 10200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -21000000
            },
            {
              "concept": "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Gains (losses) on net investment hedges",
              "value": 25700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -28100000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -12500000.0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 2890400000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 400000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 2890000000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Contingent consideration",
              "value": 8500000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2902900000.0
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation, amortization and impairments",
              "value": 238100000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 98000000
            },
            {
              "concept": "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
              "unit": "usd",
              "label": "Loss on assets and liabilities held for sale",
              "value": -113200000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 71600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi",
              "unit": "usd",
              "label": "Unrealized (gain) loss on strategic investments",
              "value": 199200000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -91100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 2900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": -108700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -216100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 306900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 80300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 3423500000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 3255800000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 2075100000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": 300000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisition of Nightstar Therapeutics plc, net of cash acquired",
              "value": 744400000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 314000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Purchase of Ionis Pharmaceuticals, Inc. stock",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
              "unit": "usd",
              "label": "Proceeds from sales of strategic investments",
              "value": 309700000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 4000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by investing activities",
              "value": 128000000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Payments for repurchase of common stock",
              "value": 3057300000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 23600000
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net distribution to noncontrolling interest",
              "value": -4300000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 21600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -3055000000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 496500000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 2300000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-19-000017",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2019,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2019-01-01 00:00:00",
        "endDate": "2019-03-31 00:00:00",
        "filedDate": "2019-04-24 00:00:00",
        "acceptedDate": "2019-04-24 16:46:37",
        "report": {
          "bs": [
            {
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 2243200000,
              "concept": "CashAndCashEquivalentsAtCarryingValue"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1665800000,
              "concept": "AvailableForSaleSecuritiesDebtSecuritiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 2088900000,
              "concept": "AccountsReceivableNetCurrent"
            },
            {
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 527100000,
              "concept": "biib:DuefromantiCD20therapeuticprograms"
            },
            {
              "unit": "usd",
              "label": "Components of inventories",
              "value": 770200000,
              "concept": "InventoryNet"
            },
            {
              "unit": "usd",
              "label": "Assets held for sale",
              "value": 682000000,
              "concept": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent"
            },
            {
              "unit": "usd",
              "label": "Other current assets",
              "value": 965400000,
              "concept": "OtherAssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Current assets:",
              "value": 8942600000,
              "concept": "AssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1372700000,
              "concept": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3013800000,
              "concept": "PropertyPlantAndEquipmentNet"
            },
            {
              "unit": "usd",
              "label": "Operating lease assets",
              "value": 447800000,
              "concept": "OperatingLeaseRightOfUseAsset"
            },
            {
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3056200000,
              "concept": "IntangibleAssetsNetExcludingGoodwill"
            },
            {
              "unit": "usd",
              "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
              "value": 5639700000,
              "concept": "Goodwill"
            },
            {
              "unit": "usd",
              "label": "Deferred tax asset",
              "value": 2074400000,
              "concept": "DeferredTaxAssetsLiabilitiesNetNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1898300000,
              "concept": "OtherAssetsNoncurrent"
            },
            {
              "unit": "usd",
              "label": "ASSETS",
              "value": 26445500000,
              "concept": "Assets"
            },
            {
              "unit": "usd",
              "label": "Taxes payable",
              "value": 238500000,
              "concept": "TaxesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts payable",
              "value": 378000000,
              "concept": "AccountsPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Liabilities held for sale",
              "value": 97200000,
              "concept": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2435000000,
              "concept": "OtherLiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current liabilities:",
              "value": 3148700000,
              "concept": "LiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Notes payable",
              "value": 5943200000,
              "concept": "LongTermDebt"
            },
            {
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 1741700000,
              "concept": "DeferredTaxLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Long-term operating lease liabilities",
              "value": 436100000,
              "concept": "OperatingLeaseLiabilityNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1353800000,
              "concept": "OtherLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 12623500000,
              "concept": "Liabilities"
            },
            {
              "unit": "usd",
              "label": "Commitments and contingencies",
              "value": "N/A",
              "concept": "CommitmentsAndContingencies"
            },
            {
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0,
              "concept": "PreferredStockValue"
            },
            {
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000,
              "concept": "CommonStockValue"
            },
            {
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0,
              "concept": "AdditionalPaidInCapital"
            },
            {
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -219800000,
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Retained earnings",
              "value": 17026700000,
              "concept": "RetainedEarningsAccumulatedDeficit"
            },
            {
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000,
              "concept": "TreasuryStockValue"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 13829900000,
              "concept": "StockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -7900000,
              "concept": "MinorityInterest"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 13822000000,
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 26445500000,
              "concept": "LiabilitiesAndStockholdersEquity"
            }
          ],
          "cf": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1408800000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Depreciation, amortization and impairments",
              "value": 121100000,
              "concept": "DepreciationDepletionAndAmortization"
            },
            {
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0,
              "concept": "ResearchAndDevelopmentInProcess"
            },
            {
              "unit": "usd",
              "label": "Equity Award [Domain]",
              "value": 45700000,
              "concept": "ShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "Contingent consideration",
              "value": -11500000,
              "concept": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"
            },
            {
              "unit": "usd",
              "label": "Loss on assets and liabilities held for sale",
              "value": -115500000,
              "concept": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax"
            },
            {
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 228000000,
              "concept": "DeferredIncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Unrealized (gain) loss on strategic investments",
              "value": 375000000,
              "concept": "EquitySecuritiesFvNiUnrealizedGainLoss"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": -50700000,
              "concept": "OtherNoncashIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 136600000,
              "concept": "IncreaseDecreaseInAccountsReceivable"
            },
            {
              "unit": "usd",
              "label": "Inventory",
              "value": -129000000,
              "concept": "IncreaseDecreaseInInventories"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -138400000,
              "concept": "IncreaseDecreaseInAccruedLiabilities"
            },
            {
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 170300000,
              "concept": "IncreaseDecreaseInAccruedIncomeTaxesPayable"
            },
            {
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 171100000,
              "concept": "IncreaseDecreaseInOtherOperatingCapitalNet"
            },
            {
              "unit": "usd",
              "label": "Cash flows from operating activities:",
              "value": 1459500000,
              "concept": "NetCashProvidedByUsedInOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 1489200000,
              "concept": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"
            },
            {
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 825000000,
              "concept": "PaymentsToAcquireAvailableForSaleSecuritiesDebt"
            },
            {
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": 300000000,
              "concept": "PaymentsToAcquireOtherProductiveAssets"
            },
            {
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 127100000,
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0,
              "concept": "PaymentsToAcquireInProcessResearchAndDevelopment"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": -1700000,
              "concept": "PaymentsForProceedsFromOtherInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from investing activities:",
              "value": 238800000,
              "concept": "NetCashProvidedByUsedInInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Payments for repurchase of common stock",
              "value": 655800000,
              "concept": "PaymentsForRepurchaseOfCommonStock"
            },
            {
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 32200000,
              "concept": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 8700000,
              "concept": "ProceedsFromPaymentsForOtherFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from financing activities:",
              "value": -679300000,
              "concept": "NetCashProvidedByUsedInFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 1019000000,
              "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -400000,
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents"
            }
          ],
          "ic": [
            {
              "unit": "usd",
              "label": "Numerator:",
              "value": 1408800000,
              "concept": "NetIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 6900000,
              "concept": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 16900000,
              "concept": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Gain (losses) on net investment hedge",
              "value": 14000000,
              "concept": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -600000,
              "concept": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -17800000,
              "concept": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Other comprehensive income (loss), net of tax",
              "value": 20600000,
              "concept": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 1429400000,
              "concept": "ComprehensiveIncomeNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0,
              "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1429400000,
              "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Other Revenues",
              "value": 3489800000,
              "concept": "Revenues"
            },
            {
              "unit": "usd",
              "label": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
              "value": 602000000,
              "concept": "CostOfGoodsAndServicesSold"
            },
            {
              "unit": "usd",
              "label": "Research and development",
              "value": 563700000,
              "concept": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"
            },
            {
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 567700000,
              "concept": "SellingGeneralAndAdministrativeExpense"
            },
            {
              "unit": "usd",
              "label": "Loss on assets and liabilities held for sale",
              "value": 115500000,
              "concept": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"
            },
            {
              "unit": "usd",
              "label": "Amortization and impairment of acquired intangible assets",
              "value": 68200000,
              "concept": "AmortizationOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 58100000,
              "concept": "biib:Collaborationprofitlosssharing"
            },
            {
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 0,
              "concept": "ResearchAndDevelopmentInProcess"
            },
            {
              "unit": "usd",
              "label": "Contingent consideration",
              "value": -11500000,
              "concept": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"
            },
            {
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 400000,
              "concept": "RestructuringCharges"
            },
            {
              "unit": "usd",
              "label": "Cost and expenses:",
              "value": 1987100000,
              "concept": "CostsAndExpenses"
            },
            {
              "unit": "usd",
              "label": "Income from operations",
              "value": 1502700000,
              "concept": "OperatingIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Nonoperating Income (Expense)",
              "value": 357300000,
              "concept": "NonoperatingIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1860000000,
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Income Tax Expense (Benefit)",
              "value": 422500000,
              "concept": "IncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Loss recorded on Samsung Bioepis joint venture",
              "value": -28700000,
              "concept": "IncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1408800000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 0,
              "concept": "NetIncomeLossAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd/shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 7.17,
              "concept": "EarningsPerShareBasic"
            },
            {
              "unit": "usd/shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 7.15,
              "concept": "EarningsPerShareDiluted"
            },
            {
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 196600000,
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic"
            },
            {
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 197000000,
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding"
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-18-000032",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2018,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2018-01-01 00:00:00",
        "endDate": "2018-09-30 00:00:00",
        "filedDate": "2018-10-23 00:00:00",
        "acceptedDate": "2018-10-23 16:25:54",
        "report": {
          "bs": [
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 508400000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 342300000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 2017300000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Balance, as of the end of the period",
              "value": -248300000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 47800000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 25492200000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 8719000000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2041700000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1244500000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the period",
              "value": 2386700000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 0
            },
            {
              "concept": "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent",
              "unit": "usd",
              "label": "Deferred tax assets",
              "value": 2160900000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liabilities",
              "value": 1114600000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 5440100000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3379000000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory, current",
              "value": 916600000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 11732400000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 25492200000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3174900000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 5931100000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "NCI, end of period",
              "value": -6800000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 848300000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1009800000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 2578500000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1511800000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3538900000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 16944100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 13766600000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 13759800000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 254100000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            }
          ],
          "ic": [
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 129200000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 493200000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 3552500000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -45200000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 3597700000
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 1327800000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 5481100000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 16
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 16
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 91600000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 4485100000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 956000000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 3483900000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 45200000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Total other income (expense), net",
              "value": 39600000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 4445500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -1800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 109000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment, net of tax",
              "value": -38800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 68600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -200000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 3529100000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1985600000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 112500000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 9200000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Product revenues",
              "value": 9926600000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1515200000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 207000000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 206600000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 836300000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -44800000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 686900000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -23400000
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 91600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 254000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 315600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 100700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 31900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 81000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -3035000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -421000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 4292300000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 68200000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -1200000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Payments for repurchase of common stock",
              "value": 3000000000
            },
            {
              "concept": "us-gaap_PaymentsOfCapitalDistribution",
              "unit": "usd",
              "label": "Net cash contribution to Bioverativ Inc.",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 6700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 6093800000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 112500000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 3000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Purchase of Ionis Pharmaceuticals, Inc. stock",
              "value": 462900000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": 1200000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 544700000
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Payments to Neurimmune",
              "value": 36900000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 11800000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 7994700000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 3529100000
            },
            {
              "concept": "us-gaap_RepaymentsOfNotesPayable",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 3200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 112500000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 119000000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-18-000019",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2018,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2018-01-01 00:00:00",
        "endDate": "2018-06-30 00:00:00",
        "filedDate": "2018-07-24 00:00:00",
        "acceptedDate": "2018-07-24 16:53:51",
        "report": {
          "bs": [
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 481900000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 295700000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1951000000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -261600000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 23952900000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7432100000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1974000000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1160200000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1250200000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 0
            },
            {
              "concept": "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent",
              "unit": "usd",
              "label": "Deferred tax assets",
              "value": 2217900000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liabilities",
              "value": 1160800000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 5170300000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3661300000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 931700000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 11699200000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 23952900000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3152400000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 5928400000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -7200000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 843300000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 902100000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 2633700000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1457600000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3409000000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 15499500000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 12260900000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 12253700000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 223000000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            }
          ],
          "ic": [
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 81700000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 211300000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 2094800000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -46700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 2141500000
            },
            {
              "concept": "us-gaap_CostOfGoodsAndServicesSold",
              "unit": "usd",
              "label": "Inventory charges",
              "value": 867000000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 3739700000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 9
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 9
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Loss (gain) on fair value remeasurement of contingent consideration",
              "value": 3700000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 2672400000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 586200000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 2039500000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 46700000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -75500000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 2747900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -1600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": 103800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment, net of tax",
              "value": -47300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 55300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -400000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2086200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1477700000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 85000000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 3200000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Product revenues",
              "value": 6487600000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1017500000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 209500000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 209200000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": -305600000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -57400000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 340400000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -18000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 187200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 183400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 13300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 40100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -8700000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -3060100000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) investing activities",
              "value": 198100000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 2556400000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -42400000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -2900000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 3000000000
            },
            {
              "concept": "us-gaap_PaymentsOfCapitalDistribution",
              "unit": "usd",
              "label": "Net cash contribution to Bioverativ Inc.",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 14300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 4774300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 85000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 3000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Purchase of Ionis Pharmaceuticals, Inc. stock",
              "value": 463700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": 900000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 381500000
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Payments to Neurimmune",
              "value": 38900000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -3700000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 6802700000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2086200000
            },
            {
              "concept": "us-gaap_RepaymentsOfNotesPayable",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 3200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 85000000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 81700000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-18-000010",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2018,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2018-01-01 00:00:00",
        "endDate": "2018-03-31 00:00:00",
        "filedDate": "2018-04-24 00:00:00",
        "acceptedDate": "2018-04-24 16:53:10",
        "report": {
          "bs": [
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 553500000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 345800000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1939200000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Balance, as of the end of the period",
              "value": -303900000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 26090100000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 10195400000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1808000000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1200200000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the period",
              "value": 4108000000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 3300000
            },
            {
              "concept": "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent",
              "unit": "usd",
              "label": "Deferred tax assets",
              "value": 2277400000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liabilities",
              "value": 1331100000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 4907800000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3794500000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory, current",
              "value": 890800000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 12052600000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 26090100000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3152100000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 5929400000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "NCI, end of period",
              "value": -16200000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 895900000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 380100000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 2571100000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 1640000000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 3334700000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 17334600000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 14053700000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 14037500000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 231900000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            }
          ],
          "ic": [
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 42500000
            },
            {
              "concept": "biib_RevenuesfromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Total revenues from anti-CD20 therapeutic programs",
              "value": 443200000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 103900000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 1185900000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 1700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1184200000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 446000000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 1596400000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 5
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 5
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Changes in fair value",
              "value": 5600000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1493700000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 322500000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 1172900000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": -1700000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -41000000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 1534700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -2200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -29000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 44700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Net current period other comprehensive income loss",
              "value": 13000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 500000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 164400000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1171200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 496700000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 10000000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 1600000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 3131100000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Other revenues from anti-cd20 therapeutic programs",
              "value": 2523500000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 501300000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 211700000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 211400000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net (decrease) increase in cash and cash equivalents",
              "value": 2535100000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 53100000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 168900000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 134000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 257600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -121800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": -2600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 20000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -268600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) investing activities",
              "value": 1346600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 1457100000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -26100000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -1600000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 250000000
            },
            {
              "concept": "us-gaap_PaymentsOfCapitalDistribution",
              "unit": "usd",
              "label": "Net cash contribution to Bioverativ Inc.",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 21200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1919200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 10000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration paid related to Fumapharm AG acquisition",
              "value": 600000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 194700000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 2600000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 4068900000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1171200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 10000000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 43400000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-17-000029",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2017,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2017-01-01 00:00:00",
        "endDate": "2017-09-30 00:00:00",
        "filedDate": "2017-10-24 00:00:00",
        "acceptedDate": "2017-10-24 16:35:34",
        "report": {
          "bs": [
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 518000000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 298700000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1567500000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -329400000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 59200000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 23073200000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7568000000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1960200000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 3062000000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1548100000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and other financing arrangements",
              "value": 573200000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 120700000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 4127500000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4019400000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1007200000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10224300000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 23073200000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3448400000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 5938300000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "NCI, end of period",
              "value": -11600000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 967000000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1300400000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 2455200000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 716900000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 2995900000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 16107700000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 12860500000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 12848900000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 121300000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            }
          ],
          "ic": [
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 82500000
            },
            {
              "concept": "biib_RevenuesfromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Revenues from anti-CD20 therapeutic programs",
              "value": 1144200000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 674900000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 2827000000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 100000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 2826900000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales",
              "value": 1120800000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 5088500000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 13
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 13
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": -61200000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 3729000000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 892600000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 2836500000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to NCI, net of tax",
              "value": -100000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -149400000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 3878400000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 6600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -162300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 146700000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -9500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 500000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 180400000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2836400000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1666000000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 120000000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 8966900000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 7642300000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1363100000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 213300000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 213000000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net (decrease) increase in cash and cash equivalents",
              "value": -832800000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -39700000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation, amortization and acquired in-process research and development",
              "value": 992000000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 54400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 225800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": 170500000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -504500000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 170300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 250200000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -1671900000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -2193600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 3032700000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -126900000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 5100000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 1365400000
            },
            {
              "concept": "us-gaap_PaymentsOfCapitalDistribution",
              "unit": "usd",
              "label": "Net cash contribution to Bioverativ Inc.",
              "value": 302700000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 10700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 4093900000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 120000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 910400000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 900000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 636800000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 10100000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 4472600000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2836400000
            },
            {
              "concept": "us-gaap_RepaymentsOfBankDebt",
              "unit": "usd",
              "label": "Repayments of Bank Debt",
              "value": 3200000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 97400000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-17-000024",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2017,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2017-01-01 00:00:00",
        "endDate": "2017-06-30 00:00:00",
        "filedDate": "2017-07-25 00:00:00",
        "acceptedDate": "2017-07-25 16:22:11",
        "report": {
          "bs": [
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 502900000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 330300000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1630200000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Balance, as of the end of the period",
              "value": -338800000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 19300000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 21759000000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7108700000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1723500000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2632700000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1169500000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and other financing arrangements",
              "value": 559900000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 100800000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 3870400000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4051300000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory, current",
              "value": 936500000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10185400000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 21759000000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 3379700000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 5954000000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -11600000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 1146100000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1268300000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 2436900000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 750900000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 2827600000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 14881700000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 11585200000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 11573600000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 52600000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            }
          ],
          "ic": [
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 47300000
            },
            {
              "concept": "biib_RevenuesfromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Revenues from anti-CD20 therapeutic programs",
              "value": 737700000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 566000000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 1591500000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 100000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1591400000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 750800000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 3664200000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 7
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 7
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Changes in fair value",
              "value": -31200000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 2119100000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax benefit (expense)",
              "value": 508800000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc",
              "value": 1610400000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to NCI, net of tax",
              "value": -100000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -105800000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 2224900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 5600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -126800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 102800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Net current period other comprehensive income loss",
              "value": -18900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": 500000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 131600000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1610300000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1219600000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 120000000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 5889100000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 5019800000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 929300000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 214000000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 213700000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net (decrease) increase in cash and cash equivalents",
              "value": -1194800000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -20500000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation, amortization and acquired in-process research and development",
              "value": 814600000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 37800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 301200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -114700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -452300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 85300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 187300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -1652400000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -946800000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 1404400000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -73500000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 7300000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 1365400000
            },
            {
              "concept": "us-gaap_PaymentsOfCapitalDistribution",
              "unit": "usd",
              "label": "Net cash contribution to Bioverativ Inc.",
              "value": 302700000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 17800000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 2536000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 120000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 860300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 600000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 407700000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 33500000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 3584500000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1610300000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 67300000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-17-000017",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2017,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2017-01-01 00:00:00",
        "endDate": "2017-03-31 00:00:00",
        "filedDate": "2017-04-25 00:00:00",
        "acceptedDate": "2017-04-25 16:18:28",
        "report": {
          "bs": [
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 324500000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 316400000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1501500000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Balance, as of the end of the period",
              "value": -325200000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 21195900000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 6859700000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1956200000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2825200000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the period",
              "value": 924000000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and other financing arrangements",
              "value": 561500000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Deferred tax liability",
              "value": 94500000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 3611700000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4103900000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 921600000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 9728500000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 21195900000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 2992500000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 5952700000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "NCI, end of period",
              "value": -11600000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 1231900000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1184500000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 2044600000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 688800000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 2610900000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 14781200000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 11479000000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 11467400000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 70000000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2977100000
            }
          ],
          "ic": [
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": 20800000
            },
            {
              "concept": "biib_RevenuesfromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Revenues from anti-CD20 therapeutic programs",
              "value": 340600000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 448500000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 742300000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 100000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 742200000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales",
              "value": 384600000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 1786400000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 3
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 3
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Changes in fair value",
              "value": -10000000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 986700000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax benefit (expense)",
              "value": 239200000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 747600000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to NCI, net of tax",
              "value": -100000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -37600000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 1024300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": -1600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -23800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 20000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -5300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation, net of tax",
              "value": -100000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 90000000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 747500000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 423400000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 2810700000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 2380100000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 499100000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 215900000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 215600000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net decrease in cash and cash equivalents",
              "value": -1410400000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 76100000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 512000000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 7900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 195700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Income tax assets and liabilities",
              "value": -195100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -684200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 46200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 34300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -901400000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -744200000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 235200000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -18100000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 6600000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 583600000
            },
            {
              "concept": "us-gaap_PaymentsOfCapitalDistribution",
              "unit": "usd",
              "label": "Net cash contribution to Bioverativ",
              "value": 302700000
            },
            {
              "concept": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
              "unit": "usd",
              "label": "Payments related to issuance of stock for share-based compensation arrangements, net",
              "value": 25500000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1256700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 855200000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 300000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 210000000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 10400000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 1884300000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 747500000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 37000000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-16-000071",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2016,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2016-01-01 00:00:00",
        "endDate": "2016-09-30 00:00:00",
        "filedDate": "2016-10-26 00:00:00",
        "acceptedDate": "2016-10-26 16:16:21",
        "report": {
          "bs": [
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 305200000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 274000000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1467800000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -300900000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 22104900000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 8091800000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2231200000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 3096900000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the period",
              "value": 2084800000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and other financing arrangements",
              "value": 4900000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 98700000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 3419700000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3869900000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 1009700000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 9990100000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 22104900000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 2499700000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 6529600000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -2700000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 993100000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1239600000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2012000000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 862100000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 2387000000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 15030000000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 12117500000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 12114800000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 208800000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2611700000
            }
          ],
          "ic": [
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": -900000
            },
            {
              "concept": "biib_RevenuesfromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Revenues from anti-CD20 therapeutic programs",
              "value": 996300000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 281400000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 2976700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 5700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 2971000000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 1100200000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 4312600000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 13
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 13
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": -18800000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 4094800000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 1047000000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 3053600000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": -5800000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -169400000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 4264200000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 1600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -17000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -62800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -76900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -1300000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 265500000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 3047800000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1439400000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 21300000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 8576800000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 7315000000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1452400000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 219400000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 219000000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase in cash and cash equivalents",
              "value": 776100000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -56800000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 505300000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 700000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from share-based awards",
              "value": 11900000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 238100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Changes in other tax assets and liabilities, net",
              "value": -147400000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -223200000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 155100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -62100000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows (used in) provided by financing activities",
              "value": -266600000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -1903100000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 2945800000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -33400000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 12800000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 348900000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 5631700000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisitions of intangible assets",
              "value": 110400000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 900000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 434000000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 35200000
            },
            {
              "concept": "us-gaap_ProceedsFromNotesPayable",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 37900000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 5185800000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 3047800000
            },
            {
              "concept": "us-gaap_RepaymentsOfNotesPayable",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 2700000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 117800000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-16-000065",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2016,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2016-01-01 00:00:00",
        "endDate": "2016-06-30 00:00:00",
        "filedDate": "2016-07-21 00:00:00",
        "acceptedDate": "2016-07-21 17:30:12",
        "report": {
          "bs": [
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs",
              "value": 334100000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 225900000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1293000000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -282800000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 69100000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 21514800000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7447700000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2434800000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 3477600000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1362000000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and other financing arrangements",
              "value": 4800000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 105600000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 3167100000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 3967600000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 996400000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10111100000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 21514800000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 2516200000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 6538300000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": -100000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 1027400000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1153000000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2072700000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 951000000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 2301800000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 14229100000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 11403800000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 11403700000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 212800000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2611700000
            }
          ],
          "ic": [
            {
              "concept": "biib_Collaborationprofitlosssharing",
              "unit": "usd",
              "label": "Collaboration profit (loss) sharing",
              "value": -5600000
            },
            {
              "concept": "biib_RevenuesfromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Revenues from anti-CD20 therapeutic programs",
              "value": 678700000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 181700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 1961900000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 3100000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1958800000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 683300000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 2782100000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 9
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 9
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": -12900000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 2727600000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 710000000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 2020700000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": -3100000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -111300000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 2838900000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 7000000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -18300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -48400000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Net current period other comprehensive income loss",
              "value": -58800000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -900000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other",
              "value": 166900000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2017600000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 910400000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 9700000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 5621000000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 4775400000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 989700000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 219300000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 219000000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase in cash and cash equivalents",
              "value": 53900000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -30200000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 325100000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 100000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from share-based awards",
              "value": 9000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 65000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Current taxes payable",
              "value": -151700000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -162300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 128300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -50100000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by financing activities",
              "value": 34000000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -1939300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 1959200000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -19800000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 65900000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 3833300000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 600000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 263700000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 23900000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 1100000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 2823600000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2017600000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 84100000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-16-000050",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2016,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2016-01-01 00:00:00",
        "endDate": "2016-03-31 00:00:00",
        "filedDate": "2016-04-21 00:00:00",
        "acceptedDate": "2016-04-21 16:57:52",
        "report": {
          "bs": [
            {
              "concept": "biib_DuefromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Due from anti-CD20 therapeutic programs, net",
              "value": 315100000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 271300000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1395100000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -259300000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 18400000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 20674700000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 7201300000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2454700000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 3189800000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1130700000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 100000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and other financing arrangements",
              "value": 4900000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 117800000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 2917900000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4012200000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 964600000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10346600000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 20674700000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 2776600000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 6535600000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "NCI, end of period",
              "value": 1300000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 941100000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 1094600000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 2003900000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 916600000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 2258900000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 13179300000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 10326800000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 10328100000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 496500000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2611700000
            }
          ],
          "ic": [
            {
              "concept": "biib_RevenuesfromantiCD20therapeuticprograms",
              "unit": "usd",
              "label": "Revenues from anti-CD20 therapeutic programs",
              "value": 329500000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 88800000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 935600000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 1700000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 933900000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 313000000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 1348400000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 4
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 4
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Changes in fair value",
              "value": -2300000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1325600000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Recognized loss",
              "value": 0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 356400000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc",
              "value": 970900000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to NCI, net of tax",
              "value": -1700000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -52800000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 1378400000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax",
              "value": 2500000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax",
              "value": -47600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 9600000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Net current period other comprehensive income loss",
              "value": -35300000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -200000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 87900000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 969200000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 437300000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 9700000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 2726800000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 2309400000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 497300000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 219300000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 218900000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase in cash and cash equivalents",
              "value": -192400000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 8900000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 149700000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 15100000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from stock options",
              "value": 8300000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 160000000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Current taxes payable",
              "value": 225100000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -180800000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 88600000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -14800000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by financing activities",
              "value": 47400000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -1203200000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 963400000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 20200000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 43000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1914400000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 300000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 126900000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 14500000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 24600000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 1181100000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 969200000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 45300000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-15-000034",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2015,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2015-01-01 00:00:00",
        "endDate": "2015-09-30 00:00:00",
        "filedDate": "2015-10-21 00:00:00",
        "acceptedDate": "2015-10-21 16:17:55",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business, net",
              "value": 319788000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 251228000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1327780000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss), net of tax",
              "value": -157416000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 1342373000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 20728368000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 9270873000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1753499000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1947354000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the period",
              "value": 4089003000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 124000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and other financing arrangements",
              "value": 5171000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 136761000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 2408854000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4181245000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Total inventory",
              "value": 918921000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 10161425000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 20728368000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 2633968000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 6529275000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "NCI, end of period",
              "value": -5783000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 861882000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 892221000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 1918897000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Total other long-term liabilities",
              "value": 861421000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 2027821000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 11999358000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 10572726000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 10566943000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 458672000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2611713000
            }
          ],
          "ic": [
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 0
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 1005302000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 285972000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 2617511000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -49053000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 2666564000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 908579000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 4201661000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 11
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 11
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Changes in fair value",
              "value": -5887000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 3681515000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Recognized loss",
              "value": -12548000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 904475000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 2715439000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to NCI, net of tax",
              "value": 49053000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -41288000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 3722803000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $(1,320) and $(6) for the three months ended September 30, 2015 and 2014, respectively; and $(699) and $(3,021) for the nine months ended September 30, 2015 and 2014, respectively",
              "value": -1154000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on cash flow hedges, net of tax of $(187) and $302 for the three months ended September 30, 2015 and 2014, respectively; and $(229) and $307 for the nine months ended September 30, 2015 and 2014, respectively",
              "value": -40084000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -61322000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Net current period other comprehensive income loss",
              "value": -97928000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -4632000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 156557000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2764492000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1471140000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 7924464000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 6762605000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1530083000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 234659000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 234134000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase in cash and cash equivalents",
              "value": 2914437000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -185802000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 444100000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -30358000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from stock options",
              "value": 70778000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 63608000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -174532000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 150387000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 121659000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) financing activities",
              "value": 2984803000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -2746071000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 2675705000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": -31564000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 33620000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 2998190000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 4870142000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 198798000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 550000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 456885000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 45509000
            },
            {
              "concept": "us-gaap_ProceedsFromNotesPayable",
              "unit": "usd",
              "label": "Proceeds from borrowings",
              "value": 5930936000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -62147000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 3363374000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2764492000
            },
            {
              "concept": "us-gaap_RepaymentsOfNotesPayable",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 2083000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 131537000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-15-000024",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2015,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2015-01-01 00:00:00",
        "endDate": "2015-06-30 00:00:00",
        "filedDate": "2015-07-24 00:00:00",
        "acceptedDate": "2015-07-24 16:25:45",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business, net",
              "value": 323714000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 282702000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1310821000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -101025000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 4251443000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 16759171000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 5618985000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1086595000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 2101796000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1282078000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 129000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 3262000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 138403000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 2154341000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4294791000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 865738000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 4186173000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 16759171000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 2555832000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 576207000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 421000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 750039000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 751588000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 1812099000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 915731000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1837670000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 11033736000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 12572577000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 12572998000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 457769000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2611706000
            }
          ],
          "ic": [
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 0
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 668121000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 187907000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 1708280000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 4533000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1703747000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 598551000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 2795634000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 7
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 7
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": -5643000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 2325096000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": -5715000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 574382000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 1749817000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": -4818000
            },
            {
              "concept": "us-gaap_NonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -25875000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 2350971000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $(145) and $(4,029) for the three months ended June 30, 2015 and 2014, respectively; and $621 and $(3,015) for the six months ended June 30, 2015 and 2014, respectively",
              "value": 1085000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(454) and $(260) for the three months ended June 30, 2015 and 2014, respectively; and $(42) and $5 for the six months ended June 30, 2015 and 2014, respectively",
              "value": -8913000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -37818000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Net current period other comprehensive income loss",
              "value": -41537000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -4109000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other",
              "value": 107596000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1744999000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 951277000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 5146605000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 4370888000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1052256000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 235671000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 235122000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase in cash and cash equivalents",
              "value": 101342000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -90647000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 292523000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -24188000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from stock options",
              "value": 69690000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 38907000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Current taxes payable",
              "value": 102017000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -169929000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 81294000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 66374000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) financing activities",
              "value": 77219000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -1756134000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 1780257000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 5808000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 10119000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 42193000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 2045046000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 198798000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 250000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 227688000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 34727000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 14995000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 975517000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1744999000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 93677000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-15-000014",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2015,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2015-01-01 00:00:00",
        "endDate": "2015-03-31 00:00:00",
        "filedDate": "2015-04-24 00:00:00",
        "acceptedDate": "2015-04-24 16:08:55",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business, net",
              "value": 311956000
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 236128000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1389995000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -70538000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 4242426000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 15219454000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 5258896000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 673946000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1377325000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 1478051000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 129000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 3254000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 130564000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 1849852000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4353123000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Total inventory",
              "value": 825349000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 3549996000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 15219454000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 1946231000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 580672000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "NCI, end of period",
              "value": 2687000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 579599000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 640630000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 1384774000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Total other long-term liabilities",
              "value": 892529000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1739628000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 10106460000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Inc. shareholders\u2019 equity",
              "value": 11666771000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 11669458000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 322075000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2611706000
            }
          ],
          "ic": [
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 0
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 330611000
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 95903000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Inc.",
              "value": 811491000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 2267000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 809224000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 312431000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 1437088000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 3
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 3
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": -7844000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1102889000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": -834000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 281881000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Inc.",
              "value": 822541000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": -2367000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 1117875000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $766 and $1,014 for the three months ended March 31, 2015 and 2014, respectively",
              "value": 1299000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $412 and $265 for the three months ended March 31, 2015 and 2014, respectively",
              "value": 87246000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -100853000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Net current period other comprehensive income loss",
              "value": -11050000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -1258000
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -14986000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other",
              "value": 52030000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 820174000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 460549000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 2554963000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 2172322000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 560361000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Inc.",
              "value": 235630000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Inc.",
              "value": 234995000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase in cash and cash equivalents",
              "value": 311022000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 16739000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 147937000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -37895000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from stock options",
              "value": 66429000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 128287000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable",
              "unit": "usd",
              "label": "Current taxes payable",
              "value": 154017000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -205467000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 21507000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 69711000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by financing activities",
              "value": 80756000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) investing activities",
              "value": -502771000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 733037000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 32921000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 6748000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 322958000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 198798000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherProductiveAssets",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 250000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 97830000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 25614000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -11287000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 373563000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 820174000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 52063000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-14-000022",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2014,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2014-01-01 00:00:00",
        "endDate": "2014-09-30 00:00:00",
        "filedDate": "2014-10-22 00:00:00",
        "acceptedDate": "2014-10-22 16:59:38",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 233629000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Current balance included within accounts receivable, net",
              "value": 1091232000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss), net of tax",
              "value": -37987000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 4150007000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 13704142000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 4372111000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 675065000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1371431000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the period",
              "value": 1186281000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 129000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable",
              "value": 3220000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 90357000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 1541204000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4129754000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Total inventory",
              "value": 753063000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 3273257000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 13704142000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 1940647000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 583977000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests, end of period",
              "value": 3189000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 396471000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 565513000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 1544160000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 658276000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1724129000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 8400455000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Idec Inc. shareholders\u2019 equity",
              "value": 10427696000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 10430885000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 159638000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2084908000
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business, net",
              "value": 269999000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 382515000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Idec Inc.",
              "value": 2041078000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": -7660000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 2048738000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 873771000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 4262136000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 8
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 8
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Changes in fair value",
              "value": 46213000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 2795621000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Recognized loss",
              "value": -14932000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax benefit (expense)",
              "value": 721709000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc.",
              "value": 2051320000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 7660000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 2812651000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $(6) and $3,639 for the three months ended September 30, 2014 and 2013, respectively; and $(3,021) and $6,554 for the nine months ended September 30, 2014 and 2013, respectively",
              "value": -5127000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $302 and $(298) for the three months ended September 30, 2014 and 2013, respectively; and $307 and $1,182 for the nine months ended September 30, 2014 and 2013, respectively",
              "value": 64793000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -71246000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": -10242000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -1338000
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense)",
              "value": -17030000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 255367000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2058980000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1393331000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 7062649000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 5916423000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1658732000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 237449000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 236641000
            },
            {
              "concept": "biib_Collaborationprofitsharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 0
            },
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 12138000
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 890859000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 601946000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -229273000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 530508000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -18227000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from stock options",
              "value": 90423000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 297057000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 19283000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 119890000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -22904000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -242608000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -1164698000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 2009252000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 95711000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 13131000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 359981000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 2738584000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Contingent consideration related to Fumapharm AG acquisition",
              "value": 175000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisition of TYSABRI rights",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 180854000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 44960000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": -15336000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 1942871000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 2058980000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayment of borrowings under senior notes and other debt",
              "value": 2674000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 119508000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-14-000016",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2014,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2014-01-01 00:00:00",
        "endDate": "2014-06-30 00:00:00",
        "filedDate": "2014-07-23 00:00:00",
        "acceptedDate": "2014-07-23 16:22:38",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 224931000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1002328000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -26678000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 4106084000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 12917998000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 3925013000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 709869000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1010837000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the period",
              "value": 863197000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 128000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 3386000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 139092000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 1364815000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4249378000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Total inventory",
              "value": 715935000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 3352772000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 12917998000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 1916624000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 586091000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 3927000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 346787000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 611791000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 1495549000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 710965000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1756164000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 7543597000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Idec Inc. shareholders\u2019 equity",
              "value": 9561299000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 9565226000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 192758000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 2061832000
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business, net",
              "value": 286897000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 260084000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Idec Inc.",
              "value": 1195528000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income attributable to noncontrolling interests, net of tax",
              "value": -8398000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1203926000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 571132000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 2898889000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 5
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 5
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "Changes in fair value",
              "value": -3220000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1659333000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Recognized loss",
              "value": -9538000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax benefit (expense)",
              "value": 446935000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc.",
              "value": 1194462000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": 8398000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 1660073000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $4,029 and $3,569 for the three months ended June 30, 2014 and 2013, respectively; and $3,015 and $2,915 for the six months ended June 30, 2014 and 2013, respectively",
              "value": -5140000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $260 and $59 for the three months ended June 30, 2014 and 2013, respectively; and $5 and $1,480 for the six months ended June 30, 2014 and 2013, respectively",
              "value": 16551000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -10991000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 1066000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -646000
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Total other income (expense), net",
              "value": -740000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 151965000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1202860000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 976157000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 4551203000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 3799057000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1088296000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 237634000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 236729000
            },
            {
              "concept": "biib_Collaborationprofitsharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 0
            },
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 7759000
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 600181000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 263600000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -146506000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 355102000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -2965000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from stock options",
              "value": 83940000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 188961000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -30299000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 72689000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 43931000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -207485000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -624134000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 1095219000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 64213000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 10745000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 336905000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1787606000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 25000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisition of TYSABRI rights",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 118308000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 33477000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 12003000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 1317525000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1202860000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayment of borrowings under senior notes",
              "value": 0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 83856000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-14-000011",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2014,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2014-01-01 00:00:00",
        "endDate": "2014-03-31 00:00:00",
        "filedDate": "2014-04-23 00:00:00",
        "acceptedDate": "2014-04-23 13:24:07",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 212809000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 1018487000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -22355000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 4054774000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 12230131000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 3525024000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 431610000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 724272000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 828601000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 128000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 3550000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 200901000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 1232916000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4364384000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 672750000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 3089068000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 12230131000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 1594247000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable",
              "value": 591012000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 4352000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 295260000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 639269000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 1216843000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 702908000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1744266000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 6829091000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Idec Inc. shareholders\u2019 equity",
              "value": 9136711000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 9141063000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 161045000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 1724927000
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business, net",
              "value": 278316000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 143258000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Idec Inc.",
              "value": 485345000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
              "value": 228000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 485117000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 279245000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 1462262000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 2
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 2
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 799000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 665747000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": -7605000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 178414000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc.",
              "value": 479956000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income (loss) attributable to noncontrolling interests, net of tax",
              "value": -228000
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 671348000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $1,014 and $654",
              "value": 1725000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains on foreign currency forward contracts, net of tax of $265 and $1,421",
              "value": 5791000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -2944000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 5389000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains on pension benefit obligation",
              "value": -817000
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -5601000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other",
              "value": 90101000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 479728000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 528884000
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 2129751000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 1742765000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 511674000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 237849000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 236786000
            },
            {
              "concept": "biib_Collaborationprofitsharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 0
            },
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 3859000
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 296885000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 225494000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -79558000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 190963000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 545000
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from stock options",
              "value": 79456000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 197685000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -171368000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 16980000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 75338000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by (used in) financing activities",
              "value": 114875000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by investing activities",
              "value": 5993000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 104626000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 71476000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 6002000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 666211000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Payment of contingent payment for acquisition",
              "value": 25000000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 54306000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfDebt",
              "unit": "usd",
              "label": "Proceeds from borrowings under line of credit facility",
              "value": 0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 22363000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 13056000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 757512000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 479728000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayment of borrowings under senior notes",
              "value": 0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 46340000
            },
            {
              "concept": "biib_PurchasesOfReverseRepurchaseAgreements",
              "unit": "usd",
              "label": "Purchases of reverse repurchase agreements",
              "value": 0
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-13-000034",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2013,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2013-01-01 00:00:00",
        "endDate": "2013-09-30 00:00:00",
        "filedDate": "2013-10-28 00:00:00",
        "acceptedDate": "2013-10-28 14:13:40",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 166709000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Current balance included within accounts receivable, net",
              "value": 891396000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss), net of tax",
              "value": -29315000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 3987377000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 11250249000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 2643672000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 240882000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 373558000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the period",
              "value": 427811000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 128000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 3385000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 302483000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 1210718000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4580199000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Total inventory",
              "value": 614483000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 3124561000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 11250249000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 1518711000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 694894000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests, end of period",
              "value": 596000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 205635000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 636028000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 1204437000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 608473000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1806074000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 5891829000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Idec Inc. shareholders' equity",
              "value": 8125092000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 8125688000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 144180000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 1724927000
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business, net",
              "value": 263465000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 233524000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1431025000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Idec Inc",
              "value": 1431025000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 599173000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 3126085000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 5
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 5
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 2983000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1828058000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Recognized loss",
              "value": -12270000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 410753000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc",
              "value": 1405035000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 1857583000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains on securities available for sale, net of tax of $3,639 and $883 for the three months ended September 30, 2013 and 2012, respectively; and $6,554 and $1,958 for the nine months ended September 30, 2013 and 2012, respectively",
              "value": 11171000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized losses on foreign currency forward contracts, net of tax of $298 and $3,140 for the three months ended September 30, 2013 and 2012, respectively; and $1,182 and $3,118 for the nine months ended September 30, 2013 and 2012, respectively",
              "value": -5549000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 17201000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Total other comprehensive income (loss), net of tax",
              "value": 25990000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains on pension benefit obligation",
              "value": -3167000
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense)",
              "value": -29525000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 174497000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1405035000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 1021820000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charges",
              "value": 0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Revenues",
              "value": 4966349000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 3935251000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 1189194000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 238508000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 237131000
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 85357000
            },
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 17319000
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 856601000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net decrease in cash and cash equivalents",
              "value": -146328000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -166187000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 373357000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 3418000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 219860000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 182814000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -198268000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -727709000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -894692000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 1476073000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 36577000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 15954000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 400308000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 2473609000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisition of TYSABRI rights",
              "value": 3262719000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 167628000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 56367000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 68572000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 5025218000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 1405035000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayment of senior notes",
              "value": 452340000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 104851000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-13-000027",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2013,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2013-01-01 00:00:00",
        "endDate": "2013-06-30 00:00:00",
        "filedDate": "2013-07-25 00:00:00",
        "acceptedDate": "2013-07-25 16:43:15",
        "report": {
          "bs": [
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 163094000
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Current balance included within accounts receivable, net",
              "value": 861457000
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss), net of tax",
              "value": -55136000
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 3917985000
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 10841590000
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 2523221000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 275163000
            },
            {
              "concept": "us-gaap_AvailableForSaleSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 107139000
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, end of the period",
              "value": 392507000
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 128000
            },
            {
              "concept": "us-gaap_DebtCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 3188000
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 313341000
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 1210718000
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 4678884000
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Total inventory",
              "value": 570390000
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 2939445000
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and equity",
              "value": 10841590000
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 1304074000
            },
            {
              "concept": "us-gaap_LongTermDebt",
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 726388000
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 596000
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 173708000
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 533852000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 1056229000
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 595642000
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1787776000
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 5404213000
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Idec Inc. shareholders' equity",
              "value": 7901549000
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total equity",
              "value": 7902145000
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 81563000
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 1365641000
            },
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 249996000
            }
          ],
          "ic": [
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 133526000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTax",
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 917588000
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Idec Inc",
              "value": 917588000
            },
            {
              "concept": "us-gaap_CostOfGoodsSold",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 364477000
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total cost and expenses",
              "value": 1975887000
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usd/share",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 3
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usd/share",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 3
            },
            {
              "concept": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
              "unit": "usd",
              "label": "(Gain) loss on fair value remeasurement of contingent consideration",
              "value": 2886000
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1148167000
            },
            {
              "concept": "us-gaap_IncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Recognized loss",
              "value": -6100000
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 224648000
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc.",
              "value": 917419000
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income attributable to noncontrolling interests, net of tax",
              "value": 0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 1173052000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $3,569 and $47 for the three months ended June 30, 2013 and 2012, respectively; and $2,915 and $1,075 for the six months ended June 30, 2013 and 2012, respectively",
              "value": 4960000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $59 and $2,164 for the three months ended June 30, 2013 and 2012, respectively; and $1,480 and $22 for the six months ended June 30, 2013 and 2012, respectively",
              "value": 9298000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -16363000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Net current period other comprehensive income loss",
              "value": 169000
            },
            {
              "concept": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
              "unit": "usd",
              "label": "Unrealized gains on pension benefit obligation",
              "value": -2274000
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Total other income (expense), net",
              "value": -24885000
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Revenue related to technical development and technology transfer services",
              "value": 103481000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 917419000
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
              "unit": "usd",
              "label": "Research and development",
              "value": 611803000
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring charge",
              "value": 0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 3138569000
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product, net",
              "value": 2481697000
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 783610000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 238543000
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 237162000
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 85357000
            },
            {
              "concept": "biib_GainOnSaleOfRights",
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 10370000
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 553391000
            }
          ],
          "cf": [
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net decrease in cash and cash equivalents",
              "value": -175336000
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -118047000
            },
            {
              "concept": "us-gaap_DepreciationDepletionAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 225880000
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -2878000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 185688000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventories",
              "value": 129171000
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet",
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -68866000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net cash flows used in financing activities",
              "value": -409187000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net cash flows used in investing activities",
              "value": -570300000
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 804151000
            },
            {
              "concept": "us-gaap_OtherNoncashIncomeExpense",
              "unit": "usd",
              "label": "Other",
              "value": 42495000
            },
            {
              "concept": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 6874000
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 41023000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1617974000
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireIntangibleAssets",
              "unit": "usd",
              "label": "Acquisition of TYSABRI rights",
              "value": 3262719000
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 87440000
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 39002000
            },
            {
              "concept": "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities",
              "unit": "usd",
              "label": "Other",
              "value": 45174000
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 4404707000
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 917419000
            },
            {
              "concept": "us-gaap_RepaymentsOfDebt",
              "unit": "usd",
              "label": "Repayment of senior notes",
              "value": 452340000
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 67387000
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-13-000018",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2013,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2013-01-01 00:00:00",
        "endDate": "2013-03-31 00:00:00",
        "filedDate": "2013-04-25 00:00:00",
        "acceptedDate": "2013-04-25 16:01:54",
        "report": {
          "bs": [
            {
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 663302000,
              "concept": "CashAndCashEquivalentsAtCarryingValue"
            },
            {
              "unit": "usd",
              "label": "Reverse Repurchase Agreements",
              "value": 2968000000,
              "concept": "SecuritiesForReverseRepurchaseAgreements"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 0,
              "concept": "MarketableSecuritiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 753611000,
              "concept": "AccountsReceivableNetCurrent"
            },
            {
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 267429000,
              "concept": "biib:DueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Inventory",
              "value": 506557000,
              "concept": "InventoryNet"
            },
            {
              "unit": "usd",
              "label": "Other current assets",
              "value": 169939000,
              "concept": "OtherAssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Current assets:",
              "value": 5328838000,
              "concept": "AssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 0,
              "concept": "MarketableSecuritiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1736811000,
              "concept": "PropertyPlantAndEquipmentNet"
            },
            {
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1581511000,
              "concept": "IntangibleAssetsNetExcludingGoodwill"
            },
            {
              "unit": "usd",
              "label": "Goodwill",
              "value": 1210718000,
              "concept": "Goodwill"
            },
            {
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 306839000,
              "concept": "OtherAssetsNoncurrent"
            },
            {
              "unit": "usd",
              "label": "ASSETS",
              "value": 10164717000,
              "concept": "Assets"
            },
            {
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 203317000,
              "concept": "NotesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Taxes payable",
              "value": 28045000,
              "concept": "TaxesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts payable",
              "value": 165207000,
              "concept": "AccountsPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 885093000,
              "concept": "OtherLiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current liabilities:",
              "value": 1281662000,
              "concept": "LiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Notes payable and other financing arrangements",
              "value": 711831000,
              "concept": "LongTermNotesPayable"
            },
            {
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 156667000,
              "concept": "DeferredTaxLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 674951000,
              "concept": "OtherLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 2825111000,
              "concept": "Liabilities"
            },
            {
              "unit": "usd",
              "label": "Commitments and Contingencies Disclosure [Abstract]",
              "value": "N/A",
              "concept": "CommitmentsAndContingencies"
            },
            {
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0,
              "concept": "PreferredStockValue"
            },
            {
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 128000,
              "concept": "CommonStockValue"
            },
            {
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 3858955000,
              "concept": "AdditionalPaidInCapital"
            },
            {
              "unit": "usd",
              "label": "Accumulated other comprehensive loss",
              "value": -67975000,
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Retained earnings",
              "value": 4913543000,
              "concept": "RetainedEarningsAccumulatedDeficit"
            },
            {
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 1365641000,
              "concept": "TreasuryStockValue"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 7339010000,
              "concept": "StockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "Noncontrolling interests",
              "value": 596000,
              "concept": "MinorityInterest"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 7339606000,
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 10164717000,
              "concept": "LiabilitiesAndStockholdersEquity"
            }
          ],
          "cf": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 426749000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 97453000,
              "concept": "DepreciationAndAmortization"
            },
            {
              "unit": "usd",
              "label": "Share-based Compensation Expense included in consolidated statements of income",
              "value": 36757000,
              "concept": "ShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -66525000,
              "concept": "DeferredIncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 33442000,
              "concept": "OtherNoncashIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 75546000,
              "concept": "IncreaseDecreaseInAccountsReceivable"
            },
            {
              "unit": "usd",
              "label": "Inventories",
              "value": 60809000,
              "concept": "IncreaseDecreaseInInventories"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -180910000,
              "concept": "IncreaseDecreaseInAccruedLiabilities"
            },
            {
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": -35212000,
              "concept": "IncreaseDecreaseInOtherOperatingCapitalNet"
            },
            {
              "unit": "usd",
              "label": "Cash flows from operating activities:",
              "value": 178939000,
              "concept": "NetCashProvidedByUsedInOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 4329506000,
              "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1160680000,
              "concept": "PaymentsToAcquireMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Purchases of reverse repurchase agreements",
              "value": 2968000000,
              "concept": "biib:PurchasesOfReverseRepurchaseAgreements"
            },
            {
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 0,
              "concept": "PaymentsToAcquireBusinessesNetOfCashAcquired"
            },
            {
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 33289000,
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 11596000,
              "concept": "PaymentsForProceedsFromOtherInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from investing activities:",
              "value": 155941000,
              "concept": "NetCashProvidedByUsedInInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Purchase of treasury stock, value",
              "value": 41023000,
              "concept": "PaymentsForRepurchaseOfCommonStock"
            },
            {
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 21817000,
              "concept": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"
            },
            {
              "unit": "usd",
              "label": "Repayments of borrowings under senior notes",
              "value": 450000000,
              "concept": "RepaymentsOfDebt"
            },
            {
              "unit": "usd",
              "label": "Proceeds from borrowings under line of credit facility",
              "value": 200000000,
              "concept": "ProceedsFromIssuanceOfDebt"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 30782000,
              "concept": "ProceedsFromPaymentsForOtherFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from financing activities:",
              "value": -238424000,
              "concept": "NetCashProvidedByUsedInFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Net decrease in cash and cash equivalents",
              "value": 96456000,
              "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -3875000,
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents"
            }
          ],
          "ic": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 426749000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $654 and $1,122",
              "value": -1117000,
              "concept": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $1,421 and $2,143",
              "value": 11603000,
              "concept": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -1263000,
              "concept": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -24419000,
              "concept": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Other comprehensive income:",
              "value": -12670000,
              "concept": "OtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 414079000,
              "concept": "ComprehensiveIncomeNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Comprehensive loss attributable to noncontrolling interests, net of tax",
              "value": 0,
              "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Idec Inc",
              "value": 414079000,
              "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Product, net",
              "value": 1095779000,
              "concept": "SalesRevenueGoodsNet"
            },
            {
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 264606000,
              "concept": "biib:UnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 54711000,
              "concept": "OtherSalesRevenueNet"
            },
            {
              "unit": "usd",
              "label": "Revenues:",
              "value": 1415096000,
              "concept": "Revenues"
            },
            {
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 133749000,
              "concept": "CostOfRevenue"
            },
            {
              "unit": "usd",
              "label": "Research and development [Member]",
              "value": 284340000,
              "concept": "ResearchAndDevelopmentExpense"
            },
            {
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 352598000,
              "concept": "SellingGeneralAndAdministrativeExpense"
            },
            {
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 85357000,
              "concept": "biib:CollaborationProfitSharing"
            },
            {
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 51301000,
              "concept": "AmortizationOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Fair value adjustment of contingent consideration",
              "value": 2277000,
              "concept": "biib:FairValueAdjustmentOfContingentConsideration"
            },
            {
              "unit": "usd",
              "label": "Restructuring charge",
              "value": 0,
              "concept": "RestructuringCharges"
            },
            {
              "unit": "usd",
              "label": "Cost and expenses:",
              "value": 909622000,
              "concept": "CostsAndExpenses"
            },
            {
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 5051000,
              "concept": "biib:GainOnSaleOfRights"
            },
            {
              "unit": "usd",
              "label": "Income from operations",
              "value": 510525000,
              "concept": "OperatingIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -14457000,
              "concept": "OtherNonoperatingIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 496068000,
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Tax benefit",
              "value": 65508000,
              "concept": "IncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Equity in loss of investee, net of tax",
              "value": -3811000,
              "concept": "IncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Net loss attributable to noncontrolling interests, net of tax",
              "value": 0,
              "concept": "NetIncomeLossAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Net loss attributable to noncontrolling interests, net of tax",
              "value": 426749000,
              "concept": "NetIncomeLoss"
            },
            {
              "unit": "usd/shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 1.8,
              "concept": "EarningsPerShareBasic"
            },
            {
              "unit": "usd/shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 1.79,
              "concept": "EarningsPerShareDiluted"
            },
            {
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 236837000,
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic"
            },
            {
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 238304000,
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding"
            }
          ]
        }
      },
      {
        "accessNumber": "0000875045-12-000010",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2012,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2012-01-01 00:00:00",
        "endDate": "2012-09-30 00:00:00",
        "filedDate": "2012-10-25 00:00:00",
        "acceptedDate": "2012-10-25 16:15:30",
        "report": {
          "bs": [
            {
              "unit": "usd",
              "label": "Cash and cash equivalents",
              "value": 451723000,
              "concept": "CashAndCashEquivalentsAtCarryingValue"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1154071000,
              "concept": "MarketableSecuritiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current balance included within accounts receivable, net",
              "value": 661519000,
              "concept": "AccountsReceivableNetCurrent"
            },
            {
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 268965000,
              "concept": "biib:DueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Components of inventories",
              "value": 392936000,
              "concept": "InventoryNet"
            },
            {
              "unit": "usd",
              "label": "Other current assets",
              "value": 126174000,
              "concept": "OtherAssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Current assets:",
              "value": 3055388000,
              "concept": "AssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1741534000,
              "concept": "MarketableSecuritiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Total property, plant and equipment, net",
              "value": 1676583000,
              "concept": "PropertyPlantAndEquipmentNet"
            },
            {
              "unit": "usd",
              "label": "Intangible assets",
              "value": 1681232000,
              "concept": "IntangibleAssetsNetExcludingGoodwill"
            },
            {
              "unit": "usd",
              "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
              "value": 1204740000,
              "concept": "Goodwill"
            },
            {
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 271144000,
              "concept": "OtherAssetsNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Assets:",
              "value": 9630621000,
              "concept": "Assets"
            },
            {
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 453209000,
              "concept": "NotesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Taxes payable",
              "value": 44252000,
              "concept": "TaxesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts payable",
              "value": 157424000,
              "concept": "AccountsPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Total accrued expenses and other",
              "value": 866208000,
              "concept": "OtherLiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current liabilities:",
              "value": 1521093000,
              "concept": "LiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Notes payable, line of credit and other financing arrangements",
              "value": 658442000,
              "concept": "LongTermNotesPayable"
            },
            {
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 249577000,
              "concept": "DeferredTaxLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 539569000,
              "concept": "OtherLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Liabilities:",
              "value": 2968681000,
              "concept": "Liabilities"
            },
            {
              "unit": "usd",
              "label": "Commitments and contingencies",
              "value": "N/A",
              "concept": "CommitmentsAndContingencies"
            },
            {
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0,
              "concept": "PreferredStockValue"
            },
            {
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 127000,
              "concept": "CommonStockValue"
            },
            {
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 3819063000,
              "concept": "AdditionalPaidInCapital"
            },
            {
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -51115000,
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Retained earnings",
              "value": 4194551000,
              "concept": "RetainedEarningsAccumulatedDeficit"
            },
            {
              "unit": "usd",
              "label": "Repurchase of common stock, value",
              "value": 1303074000,
              "concept": "TreasuryStockValue"
            },
            {
              "unit": "usd",
              "label": "Equity",
              "value": 6659552000,
              "concept": "StockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "Noncontrolling interests, beginning of period",
              "value": 2388000,
              "concept": "MinorityInterest"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 6661940000,
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 9630621000,
              "concept": "LiabilitiesAndStockholdersEquity"
            }
          ],
          "cf": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1087906000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Depreciation and amortization",
              "value": 268772000,
              "concept": "DepreciationAndAmortization"
            },
            {
              "unit": "usd",
              "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
              "value": 88378000,
              "concept": "ShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -86858000,
              "concept": "DeferredIncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": -6043000,
              "concept": "OtherNoncashIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -18486000,
              "concept": "IncreaseDecreaseInAccountsReceivable"
            },
            {
              "unit": "usd",
              "label": "Increase (Decrease) in Inventories",
              "value": 82423000,
              "concept": "IncreaseDecreaseInInventories"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 104075000,
              "concept": "IncreaseDecreaseInAccruedLiabilities"
            },
            {
              "unit": "usd",
              "label": "Other changes in operating assets and liabilities, net",
              "value": 32389000,
              "concept": "IncreaseDecreaseInOtherOperatingCapitalNet"
            },
            {
              "unit": "usd",
              "label": "Cash flows from operating activities:",
              "value": 1371990000,
              "concept": "NetCashProvidedByUsedInOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Proceeds from maturities and sales",
              "value": 1913381000,
              "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 2192343000,
              "concept": "PaymentsToAcquireMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Acquisitions of business, net of cash acquired",
              "value": 72401000,
              "concept": "PaymentsToAcquireBusinessesNetOfCashAcquired"
            },
            {
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 185511000,
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 38014000,
              "concept": "PaymentsForProceedsFromOtherInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from investing activities:",
              "value": -574888000,
              "concept": "NetCashProvidedByUsedInInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Repurchases of common stock",
              "value": 963171000,
              "concept": "PaymentsForRepurchaseOfCommonStock"
            },
            {
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 58278000,
              "concept": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 42939000,
              "concept": "ProceedsFromPaymentsForOtherFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash flows from financing activities:",
              "value": -861954000,
              "concept": "NetCashProvidedByUsedInFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Net decrease in cash and cash equivalents",
              "value": -64852000,
              "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 2033000,
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents"
            }
          ],
          "ic": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 1087906000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $883 and $794 for the three months ended September 30, 2012 and 2011, respectively; and $1,958 and $7,101 for the nine months ended September 30, 2012 and 2011, respectively",
              "value": 3331000,
              "concept": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $3,140 and $3,848 for the three months ended September 30, 2012 and 2011, respectively; and $3,118 and $2,634 for the nine months ended September 30, 2012 and 2011, respectively",
              "value": -27457000,
              "concept": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligation",
              "value": -590000,
              "concept": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": -980000,
              "concept": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Other comprehensive income:",
              "value": -24516000,
              "concept": "OtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income",
              "value": 1063390000,
              "concept": "ComprehensiveIncomeNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income attributable to noncontrolling interests, net of tax",
              "value": 65000,
              "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Comprehensive income attributable to Biogen Idec Inc",
              "value": 1063325000,
              "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Product",
              "value": 3091398000,
              "concept": "SalesRevenueGoodsNet"
            },
            {
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 856975000,
              "concept": "biib:UnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 150147000,
              "concept": "OtherSalesRevenueNet"
            },
            {
              "unit": "usd",
              "label": "Revenues:",
              "value": 4098520000,
              "concept": "Revenues"
            },
            {
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 411666000,
              "concept": "CostOfRevenue"
            },
            {
              "unit": "usd",
              "label": "Research and development expense",
              "value": 989738000,
              "concept": "ResearchAndDevelopmentExpense"
            },
            {
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 901488000,
              "concept": "SellingGeneralAndAdministrativeExpense"
            },
            {
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 239951000,
              "concept": "biib:CollaborationProfitSharing"
            },
            {
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 151256000,
              "concept": "AmortizationOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Fair value adjustment of contingent consideration",
              "value": 23573000,
              "concept": "biib:FairValueAdjustmentOfContingentConsideration"
            },
            {
              "unit": "usd",
              "label": "Restructuring Charges [Member]",
              "value": 2225000,
              "concept": "RestructuringCharges"
            },
            {
              "unit": "usd",
              "label": "Cost and expenses:",
              "value": 2719897000,
              "concept": "CostsAndExpenses"
            },
            {
              "unit": "usd",
              "label": "Gain on sale of rights",
              "value": 31719000,
              "concept": "biib:GainOnSaleOfRights"
            },
            {
              "unit": "usd",
              "label": "Income from operations",
              "value": 1410342000,
              "concept": "OperatingIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Total other income (expense), net",
              "value": 13546000,
              "concept": "OtherNonoperatingIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 1423888000,
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Income tax expense",
              "value": 334213000,
              "concept": "IncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Recognized loss",
              "value": -1769000,
              "concept": "IncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Net income attributable to noncontrolling interests, net of tax",
              "value": 0,
              "concept": "NetIncomeLossAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc",
              "value": 1087906000,
              "concept": "NetIncomeLoss"
            },
            {
              "unit": "usd/shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 4.56,
              "concept": "EarningsPerShareBasic"
            },
            {
              "unit": "usd/shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 4.53,
              "concept": "EarningsPerShareDiluted"
            },
            {
              "unit": "shares",
              "label": "Weighted average number of common shares outstanding",
              "value": 238331000,
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic"
            },
            {
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 240137000,
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding"
            }
          ]
        }
      },
      {
        "accessNumber": "0001193125-12-312222",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2012,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2012-01-01 00:00:00",
        "endDate": "2012-06-30 00:00:00",
        "filedDate": "2012-07-24 00:00:00",
        "acceptedDate": "2012-07-24 15:43:01",
        "report": {
          "bs": [
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 949239000,
              "concept": "MarketableSecuritiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts Receivable, Net, Current",
              "value": 683841000,
              "concept": "AccountsReceivableNetCurrent"
            },
            {
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 266841000,
              "concept": "biib:DueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Inventory, Net",
              "value": 362940000,
              "concept": "InventoryNet"
            },
            {
              "unit": "usd",
              "label": "Other current assets",
              "value": 149247000,
              "concept": "OtherAssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Current assets [Abstract]",
              "value": 2868919000,
              "concept": "AssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1467909000,
              "concept": "MarketableSecuritiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1732972000,
              "concept": "IntangibleAssetsNetExcludingGoodwill"
            },
            {
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 271864000,
              "concept": "OtherAssetsNoncurrent"
            },
            {
              "unit": "usd",
              "label": "ASSETS",
              "value": 9162380000,
              "concept": "Assets"
            },
            {
              "unit": "usd",
              "label": "Notes Payable, Current",
              "value": 453045000,
              "concept": "NotesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Taxes payable",
              "value": 58315000,
              "concept": "TaxesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts payable",
              "value": 159152000,
              "concept": "AccountsPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 762353000,
              "concept": "OtherLiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current liabilities:",
              "value": 1432865000,
              "concept": "LiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Long-term Notes Payable",
              "value": 641568000,
              "concept": "LongTermNotesPayable"
            },
            {
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 282904000,
              "concept": "DeferredTaxLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 534358000,
              "concept": "OtherLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 2891695000,
              "concept": "Liabilities"
            },
            {
              "unit": "usd",
              "label": "Commitments and Contingencies",
              "value": "N/A",
              "concept": "CommitmentsAndContingencies"
            },
            {
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": "N/A",
              "concept": "PreferredStockValue"
            },
            {
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 127000,
              "concept": "CommonStockValue"
            },
            {
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 3825647000,
              "concept": "AdditionalPaidInCapital"
            },
            {
              "unit": "usd",
              "label": "Retained earnings",
              "value": 3796154000,
              "concept": "RetainedEarningsAccumulatedDeficit"
            },
            {
              "unit": "usd",
              "label": "Treasury Stock Value",
              "value": 1303074000,
              "concept": "TreasuryStockValue"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 6268297000,
              "concept": "StockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
              "value": 2388000,
              "concept": "MinorityInterest"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 6270685000,
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 9162380000,
              "concept": "LiabilitiesAndStockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "Cash and Cash Equivalents, at Carrying Value",
              "value": 456811000,
              "concept": "CashAndCashEquivalentsAtCarryingValue"
            },
            {
              "unit": "usd",
              "label": "Property, Plant and Equipment, Net",
              "value": 1622812000,
              "concept": "PropertyPlantAndEquipmentNet"
            },
            {
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 1197904000,
              "concept": "Goodwill"
            },
            {
              "unit": "usd",
              "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
              "value": -50557000,
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax"
            }
          ],
          "cf": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 689507000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Depreciation and Amortization",
              "value": 174569000,
              "concept": "DepreciationAndAmortization"
            },
            {
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 60467000,
              "concept": "ShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "Cash flows from operating activities [Abstract]]",
              "value": 830206000,
              "concept": "NetCashProvidedByUsedInOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 1423931000,
              "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Payments to Acquire Marketable Securities",
              "value": 1253934000,
              "concept": "PaymentsToAcquireMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Payments to Acquire Businesses, Net of Cash Acquired",
              "value": 72401000,
              "concept": "PaymentsToAcquireBusinessesNetOfCashAcquired"
            },
            {
              "unit": "usd",
              "label": "Payments to Acquire Property, Plant, and Equipment",
              "value": 127447000,
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 909951000,
              "concept": "PaymentsForRepurchaseOfCommonStock"
            },
            {
              "unit": "usd",
              "label": "Cash flows from financing activities:",
              "value": -833704000,
              "concept": "NetCashProvidedByUsedInFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
              "value": -55996000,
              "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -1735000,
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 21070000,
              "concept": "OtherNoncashIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 51973000,
              "concept": "IncreaseDecreaseInAccruedLiabilities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 70651000,
              "concept": "IncreaseDecreaseInOtherOperatingCapitalNet"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 22647000,
              "concept": "PaymentsForProceedsFromOtherInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 33166000,
              "concept": "ProceedsFromPaymentsForOtherFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Deferred Income Tax Expense Benefit",
              "value": -43831000,
              "concept": "DeferredIncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Increase Decrease In Accounts Receivable",
              "value": 10758000,
              "concept": "IncreaseDecreaseInAccountsReceivable"
            },
            {
              "unit": "usd",
              "label": "Cash flows from investing activities:",
              "value": -52498000,
              "concept": "NetCashProvidedByUsedInInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 43081000,
              "concept": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"
            }
          ],
          "ic": [
            {
              "unit": "usd",
              "label": "Sales Revenue, Goods, Net",
              "value": 2052288000,
              "concept": "SalesRevenueGoodsNet"
            },
            {
              "unit": "usd",
              "label": "Unconsolidated Joint Business",
              "value": 569183000,
              "concept": "biib:UnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Other revenues",
              "value": 91495000,
              "concept": "OtherSalesRevenueNet"
            },
            {
              "unit": "usd",
              "label": "Revenues:",
              "value": 2712966000,
              "concept": "Revenues"
            },
            {
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 272308000,
              "concept": "CostOfRevenue"
            },
            {
              "unit": "usd",
              "label": "Research and Development Expense",
              "value": 685521000,
              "concept": "ResearchAndDevelopmentExpense"
            },
            {
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 601856000,
              "concept": "SellingGeneralAndAdministrativeExpense"
            },
            {
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 164406000,
              "concept": "biib:CollaborationProfitSharing"
            },
            {
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 98243000,
              "concept": "AmortizationOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Restructuring Charges",
              "value": 1422000,
              "concept": "RestructuringCharges"
            },
            {
              "unit": "usd",
              "label": "Cost and expenses:",
              "value": 1837873000,
              "concept": "CostsAndExpenses"
            },
            {
              "unit": "usd",
              "label": "Income from operations",
              "value": 875093000,
              "concept": "OperatingIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": 18094000,
              "concept": "OtherNonoperatingIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Income before income tax expense and equity in loss of investee, net of tax",
              "value": 893187000,
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Income Tax Expense (Benefit)",
              "value": 203169000,
              "concept": "IncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Net income",
              "value": 689507000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
              "value": 689507000,
              "concept": "NetIncomeLoss"
            },
            {
              "unit": "usd/shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 2.88,
              "concept": "EarningsPerShareBasic"
            },
            {
              "unit": "usd/shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 2.86,
              "concept": "EarningsPerShareDiluted"
            },
            {
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 239389000,
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic"
            },
            {
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 241245000,
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding"
            },
            {
              "unit": "usd",
              "label": "Fair Value Adjustment Of Contingent Consideration",
              "value": 14117000,
              "concept": "biib:FairValueAdjustmentOfContingentConsideration"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -511000,
              "concept": "IncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
              "value": 665485000,
              "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 65000,
              "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 665550000,
              "concept": "ComprehensiveIncomeNetOfTax"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -23957000,
              "concept": "OtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -26073000,
              "concept": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -391000,
              "concept": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -103000,
              "concept": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 1828000,
              "concept": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"
            }
          ]
        }
      },
      {
        "accessNumber": "0001193125-12-200855",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2012,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2012-01-01 00:00:00",
        "endDate": "2012-03-31 00:00:00",
        "filedDate": "2012-05-01 00:00:00",
        "acceptedDate": "2012-05-01 16:22:03",
        "report": {
          "bs": [
            {
              "unit": "usd",
              "label": "Cash and Cash Equivalents, at Carrying Value",
              "value": 298139000,
              "concept": "CashAndCashEquivalentsAtCarryingValue"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 978473000,
              "concept": "MarketableSecuritiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts Receivable, Net, Current",
              "value": 684242000,
              "concept": "AccountsReceivableNetCurrent"
            },
            {
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 257351000,
              "concept": "biib:DueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Inventory",
              "value": 337619000,
              "concept": "InventoryNet"
            },
            {
              "unit": "usd",
              "label": "Other current assets",
              "value": 122126000,
              "concept": "OtherAssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Current assets [Abstract]",
              "value": 2677950000,
              "concept": "AssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1471943000,
              "concept": "MarketableSecuritiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1617459000,
              "concept": "PropertyPlantAndEquipmentNet"
            },
            {
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1783981000,
              "concept": "IntangibleAssetsNetExcludingGoodwill"
            },
            {
              "unit": "usd",
              "label": "Goodwill, end of period",
              "value": 1193279000,
              "concept": "Goodwill"
            },
            {
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 368937000,
              "concept": "OtherAssetsNoncurrent"
            },
            {
              "unit": "usd",
              "label": "ASSETS",
              "value": 9113549000,
              "concept": "Assets"
            },
            {
              "unit": "usd",
              "label": "Notes Payable, Current",
              "value": 453361000,
              "concept": "NotesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Taxes payable",
              "value": 50066000,
              "concept": "TaxesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accounts payable",
              "value": 173330000,
              "concept": "AccountsPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 660562000,
              "concept": "OtherLiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Current liabilities:",
              "value": 1337319000,
              "concept": "LiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "Long-term Notes Payable",
              "value": 626012000,
              "concept": "LongTermNotesPayable"
            },
            {
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 324264000,
              "concept": "DeferredTaxLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 517406000,
              "concept": "OtherLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 2805001000,
              "concept": "Liabilities"
            },
            {
              "unit": "usd",
              "label": "Commitments and Contingencies",
              "value": "N/A",
              "concept": "CommitmentsAndContingencies"
            },
            {
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": "N/A",
              "concept": "PreferredStockValue"
            },
            {
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 129000,
              "concept": "CommonStockValue"
            },
            {
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 4217248000,
              "concept": "AdditionalPaidInCapital"
            },
            {
              "unit": "usd",
              "label": "Accumulated other comprehensive income (loss)",
              "value": -17710000,
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "Retained earnings",
              "value": 3409308000,
              "concept": "RetainedEarningsAccumulatedDeficit"
            },
            {
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 1303074000,
              "concept": "TreasuryStockValue"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 6305901000,
              "concept": "StockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
              "value": 2647000,
              "concept": "MinorityInterest"
            },
            {
              "unit": "usd",
              "label": "Equity:",
              "value": 6308548000,
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "LIABILITIES AND EQUITY",
              "value": 9113549000,
              "concept": "LiabilitiesAndStockholdersEquity"
            }
          ],
          "cf": [
            {
              "unit": "usd",
              "label": "Net income",
              "value": 302366000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Depreciation and Amortization",
              "value": 83945000,
              "concept": "DepreciationAndAmortization"
            },
            {
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 32396000,
              "concept": "ShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 89066000,
              "concept": "IncreaseDecreaseInAccountsReceivable"
            },
            {
              "unit": "usd",
              "label": "Cash flows from operating activities:",
              "value": 194625000,
              "concept": "NetCashProvidedByUsedInOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 824434000,
              "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 677092000,
              "concept": "PaymentsToAcquireMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Payments to Acquire Businesses, Net of Cash Acquired",
              "value": 72401000,
              "concept": "PaymentsToAcquireBusinessesNetOfCashAcquired"
            },
            {
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 54551000,
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Cash flows from investing activities:",
              "value": 618000,
              "concept": "NetCashProvidedByUsedInInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 463171000,
              "concept": "PaymentsForRepurchaseOfCommonStock"
            },
            {
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 24080000,
              "concept": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"
            },
            {
              "unit": "usd",
              "label": "Cash flows from financing activities:",
              "value": -416264000,
              "concept": "NetCashProvidedByUsedInFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
              "value": -221021000,
              "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": 4618000,
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents"
            },
            {
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -3876000,
              "concept": "DeferredIncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 29073000,
              "concept": "OtherNoncashIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -82031000,
              "concept": "IncreaseDecreaseInAccruedLiabilities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 20036000,
              "concept": "IncreaseDecreaseInOtherOperatingCapitalNet"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 19772000,
              "concept": "PaymentsForProceedsFromOtherInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 22827000,
              "concept": "ProceedsFromPaymentsForOtherFinancingActivities"
            }
          ],
          "ic": [
            {
              "unit": "usd",
              "label": "Sales Revenue, Goods, Net",
              "value": 975488000,
              "concept": "SalesRevenueGoodsNet"
            },
            {
              "unit": "usd",
              "label": "Unconsolidated Joint Business",
              "value": 284552000,
              "concept": "biib:UnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "Other",
              "value": 31974000,
              "concept": "OtherSalesRevenueNet"
            },
            {
              "unit": "usd",
              "label": "Revenues:",
              "value": 1292014000,
              "concept": "Revenues"
            },
            {
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 133197000,
              "concept": "CostOfRevenue"
            },
            {
              "unit": "usd",
              "label": "Research and development",
              "value": 355962000,
              "concept": "ResearchAndDevelopmentExpense"
            },
            {
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 300089000,
              "concept": "SellingGeneralAndAdministrativeExpense"
            },
            {
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 85894000,
              "concept": "biib:CollaborationProfitSharing"
            },
            {
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 45961000,
              "concept": "AmortizationOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Restructuring Charges",
              "value": 283000,
              "concept": "RestructuringCharges"
            },
            {
              "unit": "usd",
              "label": "Cost and expenses:",
              "value": 922644000,
              "concept": "CostsAndExpenses"
            },
            {
              "unit": "usd",
              "label": "Income from operations",
              "value": 369370000,
              "concept": "OperatingIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": 15144000,
              "concept": "OtherNonoperatingIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "Total",
              "value": 384514000,
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Income tax expense",
              "value": 82148000,
              "concept": "IncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "Net income",
              "value": 302366000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
              "value": -295000,
              "concept": "NetIncomeLossAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
              "value": 302661000,
              "concept": "NetIncomeLoss"
            },
            {
              "unit": "usd/shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 1.26,
              "concept": "EarningsPerShareBasic"
            },
            {
              "unit": "usd/shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 1.25,
              "concept": "EarningsPerShareDiluted"
            },
            {
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 239754000,
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic"
            },
            {
              "unit": "shares",
              "label": "Shares used in calculating diluted earnings per share",
              "value": 241828000,
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding"
            },
            {
              "unit": "usd",
              "label": "Fair Value Adjustment Of Contingent Consideration",
              "value": 1258000,
              "concept": "biib:FairValueAdjustmentOfContingentConsideration"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 311487000,
              "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 311257000,
              "concept": "ComprehensiveIncomeNetOfTax"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -230000,
              "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "Currency translation adjustment",
              "value": 25154000,
              "concept": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on pension benefit obligations",
              "value": 189000,
              "concept": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 8891000,
              "concept": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on securities available for sale, net of tax of $ 1,122 and $6,928",
              "value": 1911000,
              "concept": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $2,143 and $2,036",
              "value": -18363000,
              "concept": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecrease"
            }
          ]
        }
      },
      {
        "accessNumber": "0000950123-11-092986",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2011,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2011-01-01 00:00:00",
        "endDate": "2011-09-30 00:00:00",
        "filedDate": "2011-10-28 00:00:00",
        "acceptedDate": "2011-10-28 16:14:30",
        "report": {
          "bs": [
            {
              "unit": "usd",
              "label": "",
              "value": 575140000,
              "concept": "CashAndCashEquivalentsAtCarryingValue"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 944381000,
              "concept": "MarketableSecuritiesCurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 581052000,
              "concept": "AccountsReceivableNetCurrent"
            },
            {
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 231582000,
              "concept": "biib:DueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 194199000,
              "concept": "OtherAssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 2837288000,
              "concept": "AssetsCurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 1349359000,
              "concept": "MarketableSecuritiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 1572259000,
              "concept": "PropertyPlantAndEquipmentNet"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 1659114000,
              "concept": "IntangibleAssetsNetExcludingGoodwill"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 1146314000,
              "concept": "Goodwill"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 237870000,
              "concept": "OtherAssetsNoncurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 8802204000,
              "concept": "Assets"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 159197000,
              "concept": "AccountsPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 674743000,
              "concept": "OtherLiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 885346000,
              "concept": "LiabilitiesCurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 1060639000,
              "concept": "LongTermNotesPayable"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 238175000,
              "concept": "DeferredTaxLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 384450000,
              "concept": "OtherLiabilitiesNoncurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 2568610000,
              "concept": "Liabilities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 4446000,
              "concept": "MinorityInterest"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 6233594000,
              "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 8802204000,
              "concept": "LiabilitiesAndStockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 3422000,
              "concept": "NotesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 47984000,
              "concept": "TaxesPayableCurrent"
            },
            {
              "unit": "usd",
              "label": "",
              "value": "N/A",
              "concept": "PreferredStockValue"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 128000,
              "concept": "CommonStockValue"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 4143429000,
              "concept": "AdditionalPaidInCapital"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 7571000,
              "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 2806523000,
              "concept": "RetainedEarningsAccumulatedDeficit"
            },
            {
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 728503000,
              "concept": "TreasuryStockValue"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 6229148000,
              "concept": "StockholdersEquity"
            },
            {
              "unit": "usd",
              "label": "",
              "value": "N/A",
              "concept": "CommitmentsAndContingencies"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 310934000,
              "concept": "InventoryNet"
            }
          ],
          "cf": [
            {
              "unit": "usd",
              "label": "",
              "value": 966476000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 270212000,
              "concept": "DepreciationAndAmortization"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 86625000,
              "concept": "ShareBasedCompensation"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 15380000,
              "concept": "GainLossOnInvestments"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 17334000,
              "concept": "IncreaseDecreaseInAccountsReceivable"
            },
            {
              "unit": "usd",
              "label": "Increase Decrease In Due From Unconsolidated Joint Business",
              "value": 9123000,
              "concept": "biib:IncreaseDecreaseInDueFromUnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 35767000,
              "concept": "IncreaseDecreaseInInventories"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 31115000,
              "concept": "IncreaseDecreaseInOtherOperatingAssets"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -56737000,
              "concept": "IncreaseDecreaseInAccruedLiabilities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -19675000,
              "concept": "IncreaseDecreaseInOtherOperatingLiabilities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 1253767000,
              "concept": "NetCashProvidedByUsedInOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "Payments to Acquire Property, Plant, and Equipment",
              "value": 137578000,
              "concept": "PaymentsToAcquirePropertyPlantAndEquipment"
            },
            {
              "unit": "usd",
              "label": "Cash flows from investing activities [Abstract]",
              "value": -1260762000,
              "concept": "NetCashProvidedByUsedInInvestingActivities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 386575000,
              "concept": "PaymentsForRepurchaseOfCommonStock"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 299466000,
              "concept": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -3032000,
              "concept": "ProceedsFromRepaymentsOfBankOverdrafts"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -177053000,
              "concept": "NetCashProvidedByUsedInFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -184048000,
              "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -410000,
              "concept": "EffectOfExchangeRateOnCashAndCashEquivalents"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 40247000,
              "concept": "ProceedsFromSaleOfEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "Payments to Acquire Marketable Securities",
              "value": 2590971000,
              "concept": "PaymentsToAcquireMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 43545000,
              "concept": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 115698000,
              "concept": "DeferredIncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 16863000,
              "concept": "InventoryWriteDown"
            },
            {
              "unit": "usd",
              "label": "Impairment Of Investments And Other Assets",
              "value": 5292000,
              "concept": "biib:ImpairmentOfInvestmentsAndOtherAssets"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 15377000,
              "concept": "OtherNoncashExpense"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 1476052000,
              "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities"
            },
            {
              "unit": "usd",
              "label": "Purchases of other investments",
              "value": 6514000,
              "concept": "PaymentsToAcquireOtherInvestments"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 43545000,
              "concept": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 24112000,
              "concept": "PaymentsToMinorityShareholders"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 11460000,
              "concept": "RepaymentsOfShortTermDebt"
            },
            {
              "unit": "usd",
              "label": "Repayments On Financing Arrangement For The Sale Of The San Diego facility",
              "value": 3161000,
              "concept": "biib:RepaymentsOnFinancingArrangementForSaleOfSanDiegoFacility"
            },
            {
              "unit": "usd",
              "label": "Fair Value Adjustment of Contingent Consideration",
              "value": 5900000,
              "concept": "biib:FairValueAdjustmentOfContingentConsideration"
            },
            {
              "unit": "usd",
              "label": "Purchase of an intangible assets",
              "value": 44153000,
              "concept": "biib:PurchaseOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "Payments For Acquisition Of Noncontrolling Interest",
              "value": 91724000,
              "concept": "biib:PaymentsForAcquisitionOfNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 2155000,
              "concept": "ProceedsFromSaleOfPropertyPlantAndEquipment"
            }
          ],
          "ic": [
            {
              "unit": "usd",
              "label": "",
              "value": 2839562000,
              "concept": "SalesRevenueGoodsNet"
            },
            {
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 739054000,
              "concept": "biib:UnconsolidatedJointBusiness"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 143308000,
              "concept": "OtherSalesRevenueNet"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 3721924000,
              "concept": "Revenues"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 327143000,
              "concept": "CostOfRevenue"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 880668000,
              "concept": "ResearchAndDevelopmentExpense"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 772217000,
              "concept": "SellingGeneralAndAdministrativeExpense"
            },
            {
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 244319000,
              "concept": "biib:CollaborationProfitSharing"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 157699000,
              "concept": "AmortizationOfIntangibleAssets"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 2406336000,
              "concept": "CostsAndExpenses"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 1315588000,
              "concept": "OperatingIncomeLoss"
            },
            {
              "unit": "usd",
              "label": "",
              "value": -9504000,
              "concept": "OtherNonoperatingIncomeExpense"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 1306084000,
              "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 339608000,
              "concept": "IncomeTaxExpenseBenefit"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 966476000,
              "concept": "ProfitLoss"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 32286000,
              "concept": "NetIncomeLossAttributableToNoncontrollingInterest"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 934190000,
              "concept": "NetIncomeLoss"
            },
            {
              "unit": "shares",
              "label": "",
              "value": 242266000,
              "concept": "WeightedAverageNumberOfSharesOutstandingBasic"
            },
            {
              "unit": "shares",
              "label": "",
              "value": 245140000,
              "concept": "WeightedAverageNumberOfDilutedSharesOutstanding"
            },
            {
              "unit": "usd",
              "label": "",
              "value": 18390000,
              "concept": "RestructuringCharges"
            },
            {
              "unit": "usd/shares",
              "label": "",
              "value": 3.85,
              "concept": "EarningsPerShareBasic"
            },
            {
              "unit": "usd/shares",
              "label": "",
              "value": 3.81,
              "concept": "EarningsPerShareDiluted"
            },
            {
              "unit": "usd",
              "label": "Fair Value Adjustment of Contingent Consideration",
              "value": 5900000,
              "concept": "biib:FairValueAdjustmentOfContingentConsideration"
            }
          ]
        }
      },
      {
        "accessNumber": "0000950123-11-068367",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2011,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2011-01-01 00:00:00",
        "endDate": "2011-06-30 00:00:00",
        "filedDate": "2011-07-26 00:00:00",
        "acceptedDate": "2011-07-26 16:12:33",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 184871000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts Payable, Current",
              "value": 170746000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts Receivable, Net, Current",
              "value": 666960000.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
              "value": 25713000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional Paid in Capital",
              "value": 4224865000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Assets",
              "value": 8621979000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 2688623000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and Cash Equivalents, at Carrying Value",
              "value": 697526000.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 127000.0
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 196784000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 1146314000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible Assets, Net (Excluding Goodwill)",
              "value": 1678867000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory, Net",
              "value": 308254000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Liabilities",
              "value": 2565785000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Liabilities and Stockholders' Equity",
              "value": 8621979000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Liabilities, Current",
              "value": 954330000.0
            },
            {
              "concept": "us-gaap_LongTermNotesPayable",
              "unit": "usd",
              "label": "Long-term Notes Payable",
              "value": 1062986000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable Securities, Current",
              "value": 629218000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable Securities, Noncurrent",
              "value": 1183559000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
              "value": 79144000.0
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Notes Payable, Current",
              "value": 131981000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 201794000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 211747000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Other Liabilities, Current",
              "value": 641273000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 351685000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, Plant and Equipment, Net",
              "value": 1712869000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained Earnings (Accumulated Deficit)",
              "value": 2454848000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Stockholders' Equity",
              "value": 5977050000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
              "value": 6056194000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes Payable, Current",
              "value": 10330000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 728503000.0
            }
          ],
          "ic": [
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 162844000.0
            },
            {
              "concept": "biib_FairValueAdjustmentOfContingentConsideration",
              "unit": "usd",
              "label": "Fair Value Adjustment of Contingent Consideration",
              "value": 3400000.0
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 472583000.0
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 108352000.0
            },
            {
              "concept": "us-gaap_CostOfRevenue",
              "unit": "usd",
              "label": "Cost of Revenue",
              "value": 203616000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Costs and Expenses",
              "value": 1584895000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usdeps",
              "label": "Earnings Per Share, Basic",
              "value": 2.4
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usdeps",
              "label": "Earnings Per Share, Diluted",
              "value": 2.38
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income (Loss) from Continuing Operations before Income Taxes, Minority Interest, and Income (Loss) from Equity Method Investments",
              "value": 825318000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income Tax Expense (Benefit)",
              "value": 212504000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc.",
              "value": 582364000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
              "value": 30450000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Operating Income (Loss)",
              "value": 827095000.0
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other Nonoperating Income (Expense)",
              "value": -1777000.0
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other revenues",
              "value": 75602000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
              "value": 612814000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpense",
              "unit": "usd",
              "label": "Research and Development Expense",
              "value": 579277000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring Charges",
              "value": 16587000.0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Revenues",
              "value": 2411990000.0
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Sales Revenue, Goods, Net",
              "value": 1863805000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, General and Administrative Expense",
              "value": 510819000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 244899000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 241932000.0
            }
          ],
          "cf": [
            {
              "concept": "biib_FairValueAdjustmentOfContingentConsideration",
              "unit": "usd",
              "label": "Fair Value Adjustment of Contingent Consideration",
              "value": 3400000.0
            },
            {
              "concept": "biib_ImpairmentOfInvestmentsAndOtherAssets",
              "unit": "usd",
              "label": "Impairment Of Investments And Other Assets",
              "value": 6137000.0
            },
            {
              "concept": "biib_IncreaseDecreaseInDueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Increase Decrease In Due From Unconsolidated Joint Business",
              "value": -37588000.0
            },
            {
              "concept": "biib_PurchaseOfIntangibleAssets",
              "unit": "usd",
              "label": "Purchase of an intangible assets",
              "value": 14505000.0
            },
            {
              "concept": "biib_RepaymentsOnFinancingArrangementForSaleOfSanDiegoFacility",
              "unit": "usd",
              "label": "Repayments On Financing Arrangement For The Sale Of The San Diego facility",
              "value": 2367000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
              "value": -68266000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 48626000.0
            },
            {
              "concept": "us-gaap_DepreciationAndAmortization",
              "unit": "usd",
              "label": "Depreciation and Amortization",
              "value": 182845000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
              "value": 6194000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities",
              "value": 37827000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
              "unit": "usd",
              "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
              "value": 37827000.0
            },
            {
              "concept": "us-gaap_GainLossOnInvestments",
              "unit": "usd",
              "label": "Gain (Loss) on Investments",
              "value": 15539000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 54909000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Increase (Decrease) in Accrued Liabilities",
              "value": -67488000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Increase (Decrease) in Inventories",
              "value": 24708000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": 30354000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities and taxes payable",
              "value": -51784000.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Write-down of inventory to net realizable value",
              "value": 7296000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Financing Activities",
              "value": -77925000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Investing Activities",
              "value": -673585000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 683244000.0
            },
            {
              "concept": "us-gaap_OtherNoncashExpense",
              "unit": "usd",
              "label": "Non-cash interest (income) expense and foreign exchange remeasurement loss (gain), net",
              "value": 9748000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 386575000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireMarketableSecurities",
              "unit": "usd",
              "label": "Payments to Acquire Marketable Securities",
              "value": 1778568000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Purchases of other investments",
              "value": 3954000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Payments to Acquire Property, Plant, and Equipment",
              "value": 86229000.0
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Payments to Noncontrolling Interests",
              "value": 9930000.0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 285883000.0
            },
            {
              "concept": "us-gaap_ProceedsFromRepaymentsOfBankOverdrafts",
              "unit": "usd",
              "label": "Change in cash overdraft",
              "value": 4485000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from Sale and Maturity of Marketable Securities",
              "value": 1169836000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from Sale of Equity Method Investments",
              "value": 39835000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
              "value": 612814000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfShortTermDebt",
              "unit": "usd",
              "label": "Repayments of Short-term Debt",
              "value": 7248000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based Compensation",
              "value": 57399000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000950123-11-037561",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2011,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2011-01-01 00:00:00",
        "endDate": "2011-03-31 00:00:00",
        "filedDate": "2011-04-21 00:00:00",
        "acceptedDate": "2011-04-21 09:27:45",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 230610000.0
            },
            {
              "concept": "biib_TotalInventory",
              "unit": "usd",
              "label": "Total Inventory",
              "value": 295260000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 159136000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable balance",
              "value": 687609000.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
              "value": -992000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 3975428000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Assets",
              "value": 8293524000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 2628315000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and Cash Equivalents, at Carrying Value",
              "value": 790675000.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 125000.0
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 218504000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 1146314000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1731844000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Liabilities",
              "value": 2619224000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Liabilities and Stockholders' Equity",
              "value": 8293524000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Liabilities, Current",
              "value": 978846000.0
            },
            {
              "concept": "us-gaap_LongTermNotesPayable",
              "unit": "usd",
              "label": "Long-term Notes Payable",
              "value": 1065613000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 437870000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 885444000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
              "value": 70141000.0
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Notes Payable, Current",
              "value": 134779000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 186291000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 228105000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 591448000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 356261000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, Plant and Equipment, Net",
              "value": 1673502000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 2166813000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Shareholders equity",
              "value": 5604159000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
              "value": 5674300000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 93483000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 537215000.0
            }
          ],
          "ic": [
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 74794000.0
            },
            {
              "concept": "biib_FairValueAdjustmentOfContingentConsideration",
              "unit": "usd",
              "label": "Fair Value Adjustment of Contingent Consideration",
              "value": 1200000.0
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 256124000.0
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 53216000.0
            },
            {
              "concept": "us-gaap_CostOfRevenue",
              "unit": "usd",
              "label": "Cost of Revenue",
              "value": 103113000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Costs and Expenses",
              "value": 787059000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usdeps",
              "label": "Earnings Per Share, Basic",
              "value": 1.22
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usdeps",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 1.2
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income (Loss) from Continuing Operations before Income Taxes, Minority Interest, and Income (Loss) from Equity Method Investments",
              "value": 426234000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income Tax Expense (Benefit)",
              "value": 117468000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc.",
              "value": 294331000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
              "value": 14435000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 416283000.0
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other Nonoperating Income (Expense)",
              "value": 9951000.0
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other revenues",
              "value": 40116000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 308766000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpense",
              "unit": "usd",
              "label": "Research and Development Expense",
              "value": 293633000.0
            },
            {
              "concept": "us-gaap_RestructuringCharges",
              "unit": "usd",
              "label": "Restructuring Charges",
              "value": 16587000.0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Revenues",
              "value": 1203342000.0
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Sales Revenue, Goods, Net",
              "value": 907102000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 244516000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 244551000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 241536000.0
            }
          ],
          "cf": [
            {
              "concept": "biib_FairValueAdjustmentOfContingentConsideration",
              "unit": "usd",
              "label": "Fair Value Adjustment of Contingent Consideration",
              "value": 1200000.0
            },
            {
              "concept": "biib_ImpairmentOfInvestmentsAndOtherAssets",
              "unit": "usd",
              "label": "Impairment Of Investments And Other Assets",
              "value": 1210000.0
            },
            {
              "concept": "biib_IncreaseDecreaseInDueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Increase Decrease In Due From Unconsolidated Joint Business",
              "value": 8151000.0
            },
            {
              "concept": "biib_PurchaseOfIntangibleAssets",
              "unit": "usd",
              "label": "Purchase of an intangible assets",
              "value": 10962000.0
            },
            {
              "concept": "biib_RepaymentsOnFinancingArrangementForSaleOfSanDiegoFacility",
              "unit": "usd",
              "label": "Repayments On Financing Arrangement For The Sale Of The San Diego facility",
              "value": 1181000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
              "value": 26951000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 71974000.0
            },
            {
              "concept": "us-gaap_DepreciationAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization of fixed and intangible assets",
              "value": 92545000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
              "value": 4126000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities",
              "value": 10060000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
              "unit": "usd",
              "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
              "value": 10060000.0
            },
            {
              "concept": "us-gaap_GainLossOnInvestments",
              "unit": "usd",
              "label": "Gain (Loss) on Investments",
              "value": 15897000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 90712000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -149063000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Increase (Decrease) in Inventories",
              "value": 6498000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": 17154000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities and taxes payable",
              "value": 38441000.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Write-down of inventory to net realizable value",
              "value": 1170000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Financing Activities",
              "value": -99832000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Investing Activities",
              "value": -126795000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 253578000.0
            },
            {
              "concept": "us-gaap_OtherNoncashExpense",
              "unit": "usd",
              "label": "Non-cash interest (income) expense and foreign exchange remeasurement loss (gain), net",
              "value": 2688000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 195287000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireMarketableSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 908730000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Purchases of other investments",
              "value": 2878000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 32143000.0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 91155000.0
            },
            {
              "concept": "us-gaap_ProceedsFromRepaymentsOfBankOverdrafts",
              "unit": "usd",
              "label": "Change in cash overdraft",
              "value": -2466000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from Sale and Maturity of Marketable Securities",
              "value": 788083000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments",
              "unit": "usd",
              "label": "Proceeds from Sale of Equity Method Investments",
              "value": 39835000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 308766000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfShortTermDebt",
              "unit": "usd",
              "label": "Repayments of Short-term Debt",
              "value": 2113000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Amortization of expense associated with Share-based Compansation",
              "value": 33119000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000950123-10-096037",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2010,
        "quarter": 3,
        "form": "10-Q",
        "startDate": "2010-01-01 00:00:00",
        "endDate": "2010-09-30 00:00:00",
        "filedDate": "2010-10-26 00:00:00",
        "acceptedDate": "2010-10-26 14:10:49",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 221618000.0
            },
            {
              "concept": "biib_TotalInventory",
              "unit": "usd",
              "label": "Total Inventory",
              "value": 269313000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 143699000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 616697000.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
              "value": -9161000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 3855690000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 7394147000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 2131131000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, beginning of the period",
              "value": 626757000.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 124000.0
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 174615000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 1138621000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1715342000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 2323946000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and shareholders' equity",
              "value": 7394147000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 824480000.0
            },
            {
              "concept": "us-gaap_LongTermNotesPayable",
              "unit": "usd",
              "label": "Long-term Notes Payable",
              "value": 1068776000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 197835000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 560006000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interest, end of period",
              "value": 39506000.0
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 11296000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 198911000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 207256000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 553796000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 256075000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, Plant and Equipment, Net",
              "value": 1641791000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 1646852000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Idec Inc. shareholders' equity",
              "value": 5030695000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total shareholders' equity",
              "value": 5070201000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 115689000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 462810000.0
            }
          ],
          "ic": [
            {
              "concept": "biib_AcquiredInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 244976000.0
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 190240000.0
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 819281000.0
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 155568000.0
            },
            {
              "concept": "us-gaap_CostOfRevenue",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 299958000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total costs and expenses",
              "value": 2603648000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usdeps",
              "label": "Earnings Per Share, Basic",
              "value": 2.98
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usdeps",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 2.95
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense",
              "value": 879385000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 252564000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec",
              "value": 764995000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
              "value": -138174000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 893703000.0
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other Nonoperating Income (Expense)",
              "value": -14318000.0
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other revenues",
              "value": 117765000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 626821000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpense",
              "unit": "usd",
              "label": "Research and Development Expense",
              "value": 957759000.0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 3497351000.0
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product",
              "value": 2560305000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 755147000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 258906000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 256586000.0
            }
          ],
          "cf": [
            {
              "concept": "biib_AcquisitionOfVariableInterestNet",
              "unit": "usd",
              "label": "Acquisition Of Variable Interest Net",
              "value": 84952000.0
            },
            {
              "concept": "biib_ImpairmentOfInvestmentsAndOtherAssets",
              "unit": "usd",
              "label": "Impairment Of Investments And Other Assets",
              "value": 19319000.0
            },
            {
              "concept": "biib_IncreaseDecreaseInDueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Increase Decrease In Due From Unconsolidated Joint Business",
              "value": 27829000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 46719000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -61244000.0
            },
            {
              "concept": "us-gaap_DepreciationAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization of fixed and intangible assets",
              "value": 260089000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -1851000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities",
              "value": 6284000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
              "unit": "usd",
              "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
              "value": 6284000.0
            },
            {
              "concept": "us-gaap_GainLossOnInvestments",
              "unit": "usd",
              "label": "Realized gain on sale of marketable securities and strategic investments",
              "value": 16113000.0
            },
            {
              "concept": "us-gaap_GainsLossesOnSalesOfAssets",
              "unit": "usd",
              "label": "Gains (Losses) on Sales of Assets",
              "value": -1748000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 72719000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": 17377000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Increase (Decrease) in Inventories",
              "value": -16311000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": 22435000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities and taxes payable",
              "value": 41564000.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Write-down of inventory to net realizable value",
              "value": 9918000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Financing Activities",
              "value": -2010845000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Investing Activities",
              "value": 863947000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 1193617000.0
            },
            {
              "concept": "us-gaap_OtherNoncashExpense",
              "unit": "usd",
              "label": "Non-cash interest (income) expense and foreign exchange remeasurement loss (gain), net",
              "value": 1124000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 2077579000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Payments to Acquire Businesses, Net of Cash Acquired",
              "value": 39976000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireMarketableSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 1371769000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Purchases of other investments",
              "value": 5499000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 124220000.0
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Net distributions to noncontrolling interest",
              "value": 6401000.0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 80447000.0
            },
            {
              "concept": "us-gaap_ProceedsFromRepaymentsOfBankOverdrafts",
              "unit": "usd",
              "label": "Change in cash overdraft",
              "value": 2586000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from Sale and Maturity of Marketable Securities",
              "value": 2490363000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 626821000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfShortTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 16182000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Research And Development In Process",
              "value": 271376000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 134594000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000950123-10-066527",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2010,
        "quarter": 2,
        "form": "10-Q",
        "startDate": "2010-01-01 00:00:00",
        "endDate": "2010-06-30 00:00:00",
        "filedDate": "2010-07-20 00:00:00",
        "acceptedDate": "2010-07-20 16:23:10",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 250143000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 144476000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 548893000.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
              "value": -28422000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 4282739000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 7502150000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 2255231000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, beginning of the period",
              "value": 720962000.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 129000.0
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 207492000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 1138621000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1768929000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Total inventory",
              "value": 267878000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 2290860000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and shareholders' equity",
              "value": 7502150000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 755658000.0
            },
            {
              "concept": "us-gaap_LongTermNotesPayable",
              "unit": "usd",
              "label": "Long-term Notes Payable",
              "value": 1069725000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 248710000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 566118000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interest, end of period",
              "value": 40484000.0
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 10096000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 218645000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 201730000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 487803000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 257985000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Total",
              "value": 1571521000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 1405340000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Idec Inc. shareholders' equity",
              "value": 5170806000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total shareholders' equity",
              "value": 5211290000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 113283000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 488980000.0
            }
          ],
          "ic": [
            {
              "concept": "biib_AcquiredInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 39976000.0
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 126249000.0
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 561300000.0
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 102037000.0
            },
            {
              "concept": "us-gaap_CostOfRevenue",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 204040000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total costs and expenses",
              "value": 1621994000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usdeps",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 1.92
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usdeps",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 1.91
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense",
              "value": 692195000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 177553000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc.",
              "value": 510880000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
              "value": 3762000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 699568000.0
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other Nonoperating Income (Expense)",
              "value": -7373000.0
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other revenues",
              "value": 76807000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 514642000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpense",
              "unit": "usd",
              "label": "Research and development",
              "value": 638705000.0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 2321562000.0
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product",
              "value": 1683455000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 510987000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 267272000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 265018000.0
            }
          ],
          "cf": [
            {
              "concept": "biib_ImpairmentOfInvestmentsAndOtherAssets",
              "unit": "usd",
              "label": "Impairment Of Investments And Other Assets",
              "value": 17231000.0
            },
            {
              "concept": "biib_IncreaseDecreaseInDueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Increase Decrease In Due From Unconsolidated Joint Business",
              "value": 56354000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 149491000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": -30317000.0
            },
            {
              "concept": "us-gaap_DepreciationAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization of fixed and intangible assets",
              "value": 169961000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -10418000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities",
              "value": 5598000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
              "unit": "usd",
              "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
              "value": 5598000.0
            },
            {
              "concept": "us-gaap_GainLossOnInvestments",
              "unit": "usd",
              "label": "Gain (Loss) on Investments",
              "value": 11300000.0
            },
            {
              "concept": "us-gaap_GainsLossesOnSalesOfAssets",
              "unit": "usd",
              "label": "Gains (Losses) on Sales of Assets",
              "value": -389000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": 22955000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -23732000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Increase (Decrease) in Inventories",
              "value": -21447000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": -3637000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities and taxes payable",
              "value": 40856000.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Write-down of inventory to net realizable value",
              "value": 5654000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Financing Activities",
              "value": -1549586000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Investing Activities",
              "value": 933701000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 765376000.0
            },
            {
              "concept": "us-gaap_OtherNoncashExpense",
              "unit": "usd",
              "label": "Non-cash interest (income) expense and foreign exchange remeasurement loss (gain), net",
              "value": 6469000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchases of treasury stock",
              "value": 1609334000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Payments to Acquire Businesses, Net of Cash Acquired",
              "value": 39976000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireMarketableSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 941268000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Purchases of other investments",
              "value": 2338000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 85260000.0
            },
            {
              "concept": "us-gaap_PaymentsToMinorityShareholders",
              "unit": "usd",
              "label": "Payments to Noncontrolling Interests",
              "value": -2187000.0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 63193000.0
            },
            {
              "concept": "us-gaap_ProceedsFromRepaymentsOfBankOverdrafts",
              "unit": "usd",
              "label": "Change in cash overdraft",
              "value": 2912000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from Sale and Maturity of Marketable Securities",
              "value": 2002543000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 514642000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfShortTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 14142000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Research And Development In Process",
              "value": 39976000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 95370000.0
            }
          ]
        }
      },
      {
        "accessNumber": "0000950123-10-036233",
        "symbol": "BIIB",
        "cik": "875045",
        "year": 2010,
        "quarter": 1,
        "form": "10-Q",
        "startDate": "2010-01-01 00:00:00",
        "endDate": "2010-03-31 00:00:00",
        "filedDate": "2010-04-20 00:00:00",
        "acceptedDate": "2010-04-20 15:31:56",
        "report": {
          "bs": [
            {
              "concept": "biib_DueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": 205228000.0
            },
            {
              "concept": "us-gaap_AccountsPayableCurrent",
              "unit": "usd",
              "label": "Accounts payable",
              "value": 121356000.0
            },
            {
              "concept": "us-gaap_AccountsReceivableNetCurrent",
              "unit": "usd",
              "label": "Accounts receivable, net",
              "value": 560777000.0
            },
            {
              "concept": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
              "unit": "usd",
              "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
              "value": 22872000.0
            },
            {
              "concept": "us-gaap_AdditionalPaidInCapital",
              "unit": "usd",
              "label": "Additional paid-in capital",
              "value": 5268465000.0
            },
            {
              "concept": "us-gaap_Assets",
              "unit": "usd",
              "label": "Total assets",
              "value": 8217323000.0
            },
            {
              "concept": "us-gaap_AssetsCurrent",
              "unit": "usd",
              "label": "Total current assets",
              "value": 2409012000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
              "unit": "usd",
              "label": "Cash and cash equivalents, beginning of the period",
              "value": 639559000.0
            },
            {
              "concept": "us-gaap_CommonStockValue",
              "unit": "usd",
              "label": "Common stock, par value $0.0005 per share",
              "value": 139000.0
            },
            {
              "concept": "us-gaap_DeferredTaxLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Long-term deferred tax liability",
              "value": 248898000.0
            },
            {
              "concept": "us-gaap_Goodwill",
              "unit": "usd",
              "label": "Goodwill",
              "value": 1138621000.0
            },
            {
              "concept": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
              "unit": "usd",
              "label": "Intangible assets, net",
              "value": 1822133000.0
            },
            {
              "concept": "us-gaap_InventoryNet",
              "unit": "usd",
              "label": "Inventory",
              "value": 280038000.0
            },
            {
              "concept": "us-gaap_Liabilities",
              "unit": "usd",
              "label": "Total liabilities",
              "value": 2266729000.0
            },
            {
              "concept": "us-gaap_LiabilitiesAndStockholdersEquity",
              "unit": "usd",
              "label": "Total liabilities and shareholders' equity",
              "value": 8217323000.0
            },
            {
              "concept": "us-gaap_LiabilitiesCurrent",
              "unit": "usd",
              "label": "Total current liabilities",
              "value": 682330000.0
            },
            {
              "concept": "us-gaap_LongTermNotesPayable",
              "unit": "usd",
              "label": "Long-term Notes Payable",
              "value": 1076201000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesCurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 513115000.0
            },
            {
              "concept": "us-gaap_MarketableSecuritiesNoncurrent",
              "unit": "usd",
              "label": "Marketable securities",
              "value": 1032223000.0
            },
            {
              "concept": "us-gaap_MinorityInterest",
              "unit": "usd",
              "label": "Noncontrolling interest",
              "value": 41222000.0
            },
            {
              "concept": "us-gaap_NotesPayableCurrent",
              "unit": "usd",
              "label": "Current portion of notes payable and line of credit",
              "value": 19115000.0
            },
            {
              "concept": "us-gaap_OtherAssetsCurrent",
              "unit": "usd",
              "label": "Other current assets",
              "value": 210295000.0
            },
            {
              "concept": "us-gaap_OtherAssetsNoncurrent",
              "unit": "usd",
              "label": "Investments and other assets",
              "value": 210761000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesCurrent",
              "unit": "usd",
              "label": "Accrued expenses and other",
              "value": 432887000.0
            },
            {
              "concept": "us-gaap_OtherLiabilitiesNoncurrent",
              "unit": "usd",
              "label": "Other long-term liabilities",
              "value": 259300000.0
            },
            {
              "concept": "us-gaap_PreferredStockValue",
              "unit": "usd",
              "label": "Preferred stock, par value $0.001 per share",
              "value": 0.0
            },
            {
              "concept": "us-gaap_PropertyPlantAndEquipmentNet",
              "unit": "usd",
              "label": "Property, plant and equipment, net",
              "value": 1604573000.0
            },
            {
              "concept": "us-gaap_RetainedEarningsAccumulatedDeficit",
              "unit": "usd",
              "label": "Retained earnings",
              "value": 1131523000.0
            },
            {
              "concept": "us-gaap_StockholdersEquity",
              "unit": "usd",
              "label": "Total Biogen Idec Inc. shareholders' equity",
              "value": 5909372000.0
            },
            {
              "concept": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Total shareholders' equity",
              "value": 5950594000.0
            },
            {
              "concept": "us-gaap_TaxesPayableCurrent",
              "unit": "usd",
              "label": "Taxes payable",
              "value": 108972000.0
            },
            {
              "concept": "us-gaap_TreasuryStockValue",
              "unit": "usd",
              "label": "Treasury stock, at cost",
              "value": 513627000.0
            }
          ],
          "ic": [
            {
              "concept": "biib_AcquiredInProcessResearchAndDevelopment",
              "unit": "usd",
              "label": "Acquired in-process research and development",
              "value": 39976000.0
            },
            {
              "concept": "biib_CollaborationProfitSharing",
              "unit": "usd",
              "label": "Collaboration profit sharing",
              "value": 63557000.0
            },
            {
              "concept": "biib_UnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Unconsolidated joint business",
              "value": 254928000.0
            },
            {
              "concept": "us-gaap_AmortizationOfIntangibleAssets",
              "unit": "usd",
              "label": "Amortization of acquired intangible assets",
              "value": 48889000.0
            },
            {
              "concept": "us-gaap_CostOfRevenue",
              "unit": "usd",
              "label": "Cost of sales, excluding amortization of acquired intangible assets",
              "value": 97055000.0
            },
            {
              "concept": "us-gaap_CostsAndExpenses",
              "unit": "usd",
              "label": "Total costs and expenses",
              "value": 805171000.0
            },
            {
              "concept": "us-gaap_EarningsPerShareBasic",
              "unit": "usdeps",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 0.8
            },
            {
              "concept": "us-gaap_EarningsPerShareDiluted",
              "unit": "usdeps",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 0.8
            },
            {
              "concept": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
              "unit": "usd",
              "label": "Income before income tax expense",
              "value": 295303000.0
            },
            {
              "concept": "us-gaap_IncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Income tax expense",
              "value": 75310000.0
            },
            {
              "concept": "us-gaap_NetIncomeLoss",
              "unit": "usd",
              "label": "Net income attributable to Biogen Idec Inc.",
              "value": 217442000.0
            },
            {
              "concept": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
              "unit": "usd",
              "label": "Net income attributable to noncontrolling interest, net of tax",
              "value": 2551000.0
            },
            {
              "concept": "us-gaap_OperatingIncomeLoss",
              "unit": "usd",
              "label": "Income from operations",
              "value": 303689000.0
            },
            {
              "concept": "us-gaap_OtherNonoperatingIncomeExpense",
              "unit": "usd",
              "label": "Other income (expense), net",
              "value": -8386000.0
            },
            {
              "concept": "us-gaap_OtherSalesRevenueNet",
              "unit": "usd",
              "label": "Other revenues",
              "value": 29712000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 219993000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentExpense",
              "unit": "usd",
              "label": "Research and development",
              "value": 307030000.0
            },
            {
              "concept": "us-gaap_Revenues",
              "unit": "usd",
              "label": "Total revenues",
              "value": 1108860000.0
            },
            {
              "concept": "us-gaap_SalesRevenueGoodsNet",
              "unit": "usd",
              "label": "Product",
              "value": 824220000.0
            },
            {
              "concept": "us-gaap_SellingGeneralAndAdministrativeExpense",
              "unit": "usd",
              "label": "Selling, general and administrative",
              "value": 248664000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
              "unit": "shares",
              "label": "Diluted earnings per share attributable to Biogen Idec Inc.",
              "value": 272703000.0
            },
            {
              "concept": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
              "unit": "shares",
              "label": "Basic earnings per share attributable to Biogen Idec Inc.",
              "value": 269922000.0
            }
          ],
          "cf": [
            {
              "concept": "biib_IncreaseDecreaseInDueFromUnconsolidatedJointBusiness",
              "unit": "usd",
              "label": "Due from unconsolidated joint business",
              "value": -11439000.0
            },
            {
              "concept": "biib_NetContributionFromNoncontrollingInterests",
              "unit": "usd",
              "label": "Net contributions from noncontrolling interest",
              "value": -760000.0
            },
            {
              "concept": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
              "unit": "usd",
              "label": "Net increase (decrease) in cash and cash equivalents",
              "value": 63172000.0
            },
            {
              "concept": "us-gaap_DeferredIncomeTaxExpenseBenefit",
              "unit": "usd",
              "label": "Deferred income taxes",
              "value": 8042000.0
            },
            {
              "concept": "us-gaap_DepreciationAndAmortization",
              "unit": "usd",
              "label": "Depreciation and amortization of fixed and intangible assets",
              "value": 82510000.0
            },
            {
              "concept": "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents",
              "unit": "usd",
              "label": "Effect of exchange rate changes on cash and cash equivalents",
              "value": -5502000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from share-based compensation",
              "value": 4379000.0
            },
            {
              "concept": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
              "unit": "usd",
              "label": "Excess tax benefit from share-based compensation",
              "value": -4379000.0
            },
            {
              "concept": "us-gaap_GainLossOnInvestments",
              "unit": "usd",
              "label": "Gain (Loss) on Investments",
              "value": -4985000.0
            },
            {
              "concept": "us-gaap_ImpairmentOfInvestments",
              "unit": "usd",
              "label": "Impairment of marketable securities, investments and other assets",
              "value": 16111000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccountsReceivable",
              "unit": "usd",
              "label": "Accounts receivable",
              "value": -20201000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
              "unit": "usd",
              "label": "Accrued expenses and other current liabilities",
              "value": -82854000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInInventories",
              "unit": "usd",
              "label": "Inventory",
              "value": 12264000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingAssets",
              "unit": "usd",
              "label": "Other assets",
              "value": -13463000.0
            },
            {
              "concept": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
              "unit": "usd",
              "label": "Other liabilities and taxes payable",
              "value": 38043000.0
            },
            {
              "concept": "us-gaap_InventoryWriteDown",
              "unit": "usd",
              "label": "Write-down of inventory to net realizable value",
              "value": 2289000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Financing Activities",
              "value": -523460000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
              "unit": "usd",
              "label": "Net Cash Provided by (Used in) Investing Activities",
              "value": 249737000.0
            },
            {
              "concept": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
              "unit": "usd",
              "label": "Net cash flows provided by operating activities",
              "value": 336895000.0
            },
            {
              "concept": "us-gaap_OtherNoncashExpense",
              "unit": "usd",
              "label": "Non-cash interest (income) expense and foreign exchange remeasurement loss (gain), net",
              "value": 3982000.0
            },
            {
              "concept": "us-gaap_PaymentsForRepurchaseOfCommonStock",
              "unit": "usd",
              "label": "Purchase of treasury stock",
              "value": 577580000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
              "unit": "usd",
              "label": "Payments to Acquire Businesses, Net of Cash Acquired",
              "value": 39976000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireMarketableSecurities",
              "unit": "usd",
              "label": "Purchases of marketable securities",
              "value": 699677000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquireOtherInvestments",
              "unit": "usd",
              "label": "Purchases of other investments",
              "value": 1708000.0
            },
            {
              "concept": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
              "unit": "usd",
              "label": "Purchases of property, plant and equipment",
              "value": 38209000.0
            },
            {
              "concept": "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
              "unit": "usd",
              "label": "Proceeds from issuance of stock for share-based compensation arrangements",
              "value": 52818000.0
            },
            {
              "concept": "us-gaap_ProceedsFromRepaymentsOfBankOverdrafts",
              "unit": "usd",
              "label": "Change in cash overdraft",
              "value": -1826000.0
            },
            {
              "concept": "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities",
              "unit": "usd",
              "label": "Proceeds from sales and maturities of marketable securities",
              "value": 1029307000.0
            },
            {
              "concept": "us-gaap_ProfitLoss",
              "unit": "usd",
              "label": "Net income",
              "value": 219993000.0
            },
            {
              "concept": "us-gaap_RepaymentsOfShortTermDebt",
              "unit": "usd",
              "label": "Repayment of borrowings",
              "value": 2011000.0
            },
            {
              "concept": "us-gaap_ResearchAndDevelopmentInProcess",
              "unit": "usd",
              "label": "Research And Development In Process",
              "value": 39976000.0
            },
            {
              "concept": "us-gaap_ShareBasedCompensation",
              "unit": "usd",
              "label": "Share-based compensation",
              "value": 51006000.0
            }
          ]
        }
      }
    ],
    "symbol": "BIIB"
  }
}